program farmasi / pharmacy programme
TRANSCRIPT
PROGRAM FARMASI / PHARMACY PROGRAMME
LAPORAN TAHUNANANNUAL REPORT 2012
VISI, MISI DAN OBJEKTIF VISION, MISSION AND OBJECTIVE
CARTA ORGANISASIORGANIZATIONAL CHART
PENGURUSAN TERTINGGI TOP MANAGEMENT
PENGENALAN INTRODUCTION
SUMBER MANUSIA DAN MODAL INSAN ORGANIZATION AND HUMAN RESOURCE DEVELOPMENT
BAHAGIAN PERKHIDMATAN FARMASI PHARMACEUTICAL SERVICES DIVISION
BIRO PENGAWALAN FARMASEUTIKAL KEBANGSAAN NATIONAL PHARMACEUTICAL CONTROL BUREAU
HALATUJU WAY FORWARD
KESIMPULAN SUMMARY
JAWATANKUASA EDITORIAL EDITORIAL COMMITTEE
LAMPIRAN ANNEXURE
23458
143644
4847
50
KANDUNGAN CONTENTS
2 PROGRAM FARMASI / PHARMACY PROGRAMME
LAPORAN TAHUNANANNUAL REPORT2012
VisiMenerajui pengurusan berkualiti ke atas ubat-ubatan melalui tenaga kerja yang berdaya saing, sains dan teknologi bersesuaian dan perkongsian dengan semua pihak
yang berkepentingan.
MisiMemastikan ubat-ubatan berkualiti
untuk negara
ObjektifMemastikan semua keluaran farmaseutikal dan produk penjagaan kesihatan yang berada di pasaran adalah berkualiti, selamat, berkesan dan dikawal mengikut undang-undang yang berkaitan serta
digunakan secara rasional.
VisionLeading in quality management of medicine through a competent pharmacy workforce and appropriate science and technology development in partnership with stakeholders
MissionEnsuring quality medicines for the nation
ObjectivesEnsuring all pharmaceutical and health products in the market are of quality, safe and efficacious to relevant legislations and used rationally
3PROGRAM FARMASI / PHARMACY PROGRAMME
LAPORAN TAHUNANANNUAL REPORT 2012
DASA
R & PENG
URUS
AN
FARM
ASI
PHAR
MAC
Y POL
ICY &
MAN
AGEM
ENT
AMALAN
DAN
PERK
EMBA
NGAN
FARM
ASI
PHAR
MAC
Y PRA
CTICE A
ND
DEVE
LOPM
ENT
PENG
UATKUA
SAAN
FA
RMAS
I PH
ARMAC
Y ENF
ORCEMEN
T
BIRO
PENG
AWALAN
FA
RMAS
EUTIK
AL
KEBA
NGSA
AN
NATIO
NAL
PHAR
MAC
EUTIC
AL CO
NTRO
L BU
REAU
BAHA
GIAN
PERK
HIDM
ATAN
FA
RMAS
I NEG
ERI
STAT
E PHA
RMAC
EUTIC
AL
SERV
ICES DIVISION
HOSPITA
L KUA
LA LU
MPU
R KU
ALA LU
MPU
R HO
SPITA
L
KERJAY
A & MOD
AL IN
SAN
CARE
ER & HUM
AN CA
PITA
L FA
RMAS
I KLIN
IKAL & TE
KNIKAL
CLINICAL & TE
CHNICA
L PHA
RMAC
Y OP
ERAS
I & SIAS
ATAN
OP
ERAT
ION & INVISTIGAT
ION
DASA
R UB
AT NAS
IONA
L NA
TIONA
L MED
ICINES PO
LICY
FORM
ULAR
I & FA
RMAK
OEKO
NOMIK
FORM
ULAR
Y & PH
ARMAC
OECO
NOMICS
PELESENA
N LIC
ENSIN
G
DASA
R FA
RMAS
I PH
ARMAC
Y POL
ICY
LOGISTIK FA
RMAS
EUTIK
AL
PHAR
MAC
EUTIC
AL LO
GISTICS
PERU
NDAN
GAN
LEGISLAT
ION
PENG
URUS
AN M
AKLU
MAT
FARM
ASI
PHAR
MAC
Y INF
ORMAT
ION MAN
AGEM
ENT
SYSTEM
PERK
EMBA
NGAN
FARM
ASI
PHAR
MAC
Y DEV
ELOP
MEN
T PENG
IKLANA
N & INOV
ASI
ADVE
RTISE
MEN
T & IN
NOVA
TION
PENT
ADBIRA
N & KEWAN
GAN
ADMINIST
RATIO
N & FIN
ANCE
PENG
GUNA
AN UBA
T BER
KUALITI
QUALITY
USE OF M
EDICINES
PENC
EGAH
AN & KE
SEDA
RAN
PENG
GUNA
PR
EVEN
TION & CO
NSUM
ER
PROT
ECTIO
N
LEMBA
GA FA
RMAS
I PH
ARMAC
Y BOA
RD
HARG
A UB
AT
MED
ICINE P
RICE
PENG
ARAH
KANA
N PERK
HIDM
ATAN
FARM
ASI
SENIOR
DIRECTO
R OF
PHAR
MAC
EUTIC
AL SE
RVICES DIVISION
PUSA
T KAW
ALAN
KUALITI
CENT
RE FO
R QU
ALITY
CONT
ROL
PUSA
T PEN
DAFTAR
AN PR
ODUK
CENT
RE FO
R PR
ODUC
T REG
ISTRA
TION
PUSA
T PAS
CA PE
NDAF
TRAN
PROD
UK
CENT
RE FO
R PO
ST-‐REG
ISTRA
TION OF
PR
ODUC
T
PUSA
T KOM
PLIANS
& PE
RLESEN
AN
CENT
RE FO
R CO
MPLIANC
E &
LICEN
CING
PUSA
T PEM
BANG
UNAN
ORG
ANISA
SI CENT
RE FO
R OR
GANISA
TIONA
L DE
VELO
PMEN
T
PUST PE
NTAD
BIRA
N CENT
RE FO
R AD
MINIST
RATIO
N
TIMBA
LAN PE
NGAR
AH
DEPU
TY DIRECTO
R
PENG
ARAH
DIRE
CTOR
PE
NGAR
AH
DIRE
CTOR
PE
NGAR
AH
DIRE
CTOR
TIMBA
LAN PE
NGAR
AH
KESIH
ATAN
NEG
ERI
(FAR
MAS
I) STAT
E HEA
LTH DE
PUTY
DIRE
CTOR
(PHA
RMAC
Y)
KETU
A PE
GAWAI FA
RMAS
I CH
IEF PH
ARMAC
IST
KETU
A PR
OGRA
M FA
RMAS
I HE
AD OF P
HARM
ACY P
ROGR
AM
CA
RTA
ORG
AN
ISA
SI O
RGA
NIZ
ATIO
NA
L C
HART
4 PROGRAM FARMASI / PHARMACY PROGRAMME
LAPORAN TAHUNANANNUAL REPORT2012
PENGURUSAN TERTINGGI TOP MANAGEMENT
YBHG. DATO’ EISAH BINTI A. RAHMANPENGARAH KANAN PERKHIDMATAN FARMASI
SENIOR DIRECTOR OF PHARMACEUTICAL SERVICES
TUAN HJ. MOHD HATTA BIN AHMADPENGARAH
PENGUATKUASAAN FARMASIDIRECTOR OF PHARMACY ENFORCEMENT
DR. SALMAH BINTI BAHRIPENGARAH
AMALAN DAN PERKEMBANGAN FARMASIDIRECTOR OF PHARMACY PRACTICE AND
DEVELOPMENT
ENCIK TAN ANN LINGPENGARAH
BIRO PENGAWALAN FARMASEUTIKAL KEBANGSAAN (BPFK)
DIRECTOR OF NATIONAL PHARMACEUTICALCONTROL BUREAU (NPCB)
DR. NOUR HANAH BINTI OTHMANTIMBALAN PENGARAH
DASAR & PENGURUSAN FARMASIDEPUTY DIRECTOR OF PHARMACY
POLICY & MANAGEMENT
5PROGRAM FARMASI / PHARMACY PROGRAMME
LAPORAN TAHUNANANNUAL REPORT 2012
PENGENALAN INTRODUCTION
Program Farmasi, Kementerian Kesihatan Malaysia (KKM) merupakan agensi utama yang bertanggungjawab memastikan ubat-ubatan adalah berkualiti untuk negara. Program ini terdiri daripada empat Bahagian utama iaitu Dasar dan Pengurusan Farmasi, Amalan dan Perkembangan Farmasi, Penguatkuasaan Farmasi dan Biro Pengawalan Farmaseutikal Kebangsaan. Keempat-empat aktiviti tersebut memainkan peranan penting dalam aspek-aspek yang berbeza tetapi mempunyai satu matlamat yang sama iaitu untuk memberikan perkhidmatan farmasi yang terbaik kepada orang ramai.
The Pharmacy Programme of the Ministry of Health (MOH) is the lead agency in ensuring quality medicines for the nation. The Programme is headed by a Senior Director who is responsible of four main activities namely Policy and Pharmacy Management, Pharmacy Practice and Development, Pharmacy Enforcement and National Pharmaceutical Control Bureau (NPCB). These four main activities play important roles in different aspects and approaches but with the same objective, that is giving the best professional pharmacy service to the public.
SUMBER MANUSIA DAN MODAL INSAN
ORGANIZATIONAL AND HUMAN RESOURCE DEVELOPMENT
8 PROGRAM FARMASI / PHARMACY PROGRAMME
LAPORAN TAHUNANANNUAL REPORT2012
SUMBER MANUSIA DAN MODAL INSANORGANIZATIONAL AND HUMAN RESOURCE DEVELOPMENT
5 | L a p o r a n T a h u n a n 2 0 1 2
SUMBER MANUSIA DAN MODAL INSAN
ORGANIZATIONAL AND HUMAN RESOURCE DEVELOPMENT
Jadual 1: Bilangan Pendaftaran oleh Lembaga Farmasi (2006-2012)
Table 1: Number of Registrations by Pharmacy Board of Malaysia (2006-2012)
Perkara Description Tahun Year
2006 2007 2008 2009 2010 2011 2012 Bilangan Ahli Farmasi Baru Berdaftar Number of Newly Registered Pharmacists
437
534
617 705 739 934 918
Bilangan Ahli Farmasi Provisional Berdaftar Number of Provisionally Registered Pharmacists
529 614 722 813 925 922 1,208
Bilangan Pertubuhan Perbadanan Berdaftar Number of Registered Body Corporates
107 98 43 48 48 44 57
Bilangan Sijil Pengekalan Tahunan/Sijil Tahunan Ahli Farmasi Number of Pharmacist Annual Retention Certificates
4,292 4,422 5,924 5,507 8,852 8,746 8,968
Bilangan Sijil Pengekalan /Sijil Tahunan Pertubuhan Perbadanan Number of Body Corporate Annual Retention Certificates
270 414 371 445 663 794 548
9PROGRAM FARMASI / PHARMACY PROGRAMME
LAPORAN TAHUNANANNUAL REPORT 2012
6 | L a p o r a n T a h u n a n 2 0 1 2
Bilangan perjawatan bagi Program Farmasi di BPF, KKM adalah seperti di Jadual 2.
The number of posts for pharmacy personnel at PSD, MOH is shown in table 2.
Jadual 2: Bilangan Jawatan Anggota Farmasi di BPF, KKM
Table 2: Number of Posts of Pharmacy Personnel
7 | L a p o r a n T a h u n a n 2 0 1 2
Jadual 3: Bilangan Jawatan Anggota Farmasi di BPFK
Table 3: Number of Posts at National Pharmaceutical Control Bureau (NPCB)
Jadual 4: Bilangan Jawatan Anggota Farmasi di KKM
Table 4: Number of Posts at MOH
Bilangan perjawatan bagi Program Farmasi di BPF, KKM adalah seperti di Jadual 2.The number of posts for pharmacy personnel at PSD, MOH is shown in table 2.
10 PROGRAM FARMASI / PHARMACY PROGRAMME
LAPORAN TAHUNANANNUAL REPORT2012
7 | L a p o r a n T a h u n a n 2 0 1 2
Jadual 3: Bilangan Jawatan Anggota Farmasi di BPFK
Table 3: Number of Posts at National Pharmaceutical Control Bureau (NPCB)
Jadual 4: Bilangan Jawatan Anggota Farmasi di KKM
Table 4: Number of Posts at MOH
11PROGRAM FARMASI / PHARMACY PROGRAMME
LAPORAN TAHUNANANNUAL REPORT 2012
8 | L a p o r a n T a h u n a n 2 0 1 2
Latihan Training
Bilangan latihan yang dikendalikan dalam tahun 2012.
Number of training conducted in the year 2012.
Jadual 5: Pelaksanaan Kursus Dalam Negara BPF, KKM
Table 5: Training Conducted Locally by PSD, MOH
Jadual 6: Bilangan Latihan Dalam Negara BPFK
Table 6: Training Conducted Locally by NPCB
Jenis latihan Types of Training
Bilangan latihan No. of Training
Bilangan peserta latihan No. of Attendance
Kursus | Courses 18 501 Seminar | Seminars 5 229 Sesi CME | CME Session 28 1,431 Sesi Latihan | Training Session 86 1,246 Bengkel | Workshop 11 276 JUMLAH TOTAL 148 3,683
Jadual 7: Pelaksanaan Kursus Luar Negara BPF dan BPFK
Table 7: Training Conducted Overseas by PSD and NPCB
Tahun Year
Bil. Kursus Dijalankan No. of Courses
Conducted
Bil. Pegawai Menghadiri No. of Attendance
2012 (BPF | PSD) 6 7
2012 (BPFK | NPCB) 51 115
Tahun Year
Peringkat Ibu Pejabat HQ
Peringkat Institusi & Negeri Institution & States
Bil. Kursus Dijalankan
No. of Courses Conducted
Bil. Pegawai Menghadiri
No. of Attendance
Bil. Kursus Dijalankan
No. of Courses Conducted
Bil. Pegawai Menghadiri
No. of Attendance
2012 69 2,706 285 12,013
Latihan Training
Bilangan latihan yang dikendalikan dalam tahun 2012.Number of training conducted in the year 2012.
BAHAGIAN PERKHIDMATAN FARMASI
PHARMACEUTICAL SERVICES DIVISION
14 PROGRAM FARMASI / PHARMACY PROGRAMME
LAPORAN TAHUNANANNUAL REPORT2012
PENCAPAIAN TAHUN 2012 ACHIEVEMENTS IN YEAR 2012
BAHAGIAN PERKHIDMATAN FARMASI PHARMACEUTICAL SERVICES DIVISION
1. Perbelanjaan Produk Farmaseutikal (Ubat dan Bukan Ubat) KKM
MOH Pharmaceutical Products (Medicines and Non Drug) Expenditure
Pada tahun 2012, nilai perolehan ubat-ubatan di semua hospital dan klinik kesihatan KKM ialah sebanyak RM1,983 juta. Nilai perbelanjaan bagi ubat – ubatan tersebut meningkat sebanyak 12.2% berbanding tahun 2011. Nilai perolehan bagi bukan ubat pula sebanyak RM683.6 juta. Nilai stok penutup bagi ubat dan bukan ubat pada bulan Disember 2012 adalah RM296.1 juta, iaitu kira-kira 1.3 bulan pegangan stok.
The total cost of medicines procured in 2012 for all MOH hospitals and health clinics was RM1, 983 million. This shows an increase of 12.2% in medicines expenditure compared to 2011. The total cost of non-drug procured was RM683.6 million. The amount of closing stock for medicines and non-drug in December 2012 was RM296.1 million, which is about 1.3 months of stock holding.
9 | L a p o r a n T a h u n a n 2 0 1 2
PENCAPAIAN TAHUN 2012
ACHIEVEMENTS IN YEAR 2012
BAHAGIAN PERKHIDMATAN FARMASI
PHARMACEUTICAL SERVICES DIVISION
1. Perbelanjaan Produk Farmaseutikal (Ubat dan Bukan Ubat) KKM
MOH Pharmaceutical Products (Medicines and Non Drug) Expenditure
Pada tahun 2012, nilai perolehan ubat-ubatan di semua hospital dan klinik kesihatan KKM ialah
sebanyak RM1,983 juta. Nilai perbelanjaan bagi ubat – ubatan tersebut meningkat sebanyak 12.2%
berbanding tahun 2011. Nilai perolehan bagi bukan ubat pula sebanyak RM683.6 juta. Nilai stok
penutup bagi ubat dan bukan ubat pada bulan Disember 2012 adalah RM296.1 juta, iaitu kira-kira 1.3
bulan pegangan stok.
The total cost of medicines procured in 2012 for all MOH hospitals and health clinics was RM1, 983
million. This shows an increase of 12.2% in medicines expenditure compared to 2011. The total cost
of non-drug procured was RM683.6 million. The amount of closing stock for medicines and non-drug in
December 2012 was RM296.1 million, which is about 1.3 months of stock holding.
Jadual 8: Perbelanjaan Produk Farmaseutikal KKM (2010-2012)
Table 8: MOH Pharmaceutical Products Expenditure (2010-2012)
Tahun Year
Jumlah Perbelanjaan
(RM Juta) Total Expenditure
(RM Million)
% Peningkatan Berbanding Tahun
Sebelumnya % Increment Over the Previous Year
2010 1605.54 14.48
2011 1767.61 10.09
2012 1983.51 12.21
10 | L a p o r a n T a h u n a n 2 0 1 2
Jadual 9: Kaedah Perolehan Tahun 2012
Table 9: Types of Medicines Procurement in 2012
2. Formulari Ubat KKM
MOH Drug Formulary
Rajah 1: Penyenaraian Ubat dalam Formulari Ubat (2001-2012)
Figure 1: Drugs Listed into MOH Drug Formulary (2001-2012)
Pada tahun 2012, 3 ubat telah dikeluarkan daripada formulari manakala 51 ubat baru termasuk
kekuatan atau formulasi baru telah disenaraikan dalam formulari ubat KKM. Ini menjadikan
keseluruhan ubat dalam Formulari Ubat KKM berjumlah 1578 pada akhir tahun 2012 (Rajah 1).
In 2012, 3 drugs have been removed from the formulary while 51 drugs, including new formulations or
strengths, were listed into the formulary. As a result, there were a total of 1578 preparations in the
MOH Drug Formulary at the end of 2012 (Figure 1).
Tahun
Year
APPL
(RM)
KKM Kontrak
MOH Contract
(RM)
Pembelian Terus & Sebutharga
Local Purchase & Quotation
(RM)
2012 810,332,787 (41%) 760,829,333 (38%)
412,355,654 (21%)
15PROGRAM FARMASI / PHARMACY PROGRAMME
LAPORAN TAHUNANANNUAL REPORT 2012
10 | L a p o r a n T a h u n a n 2 0 1 2
Jadual 9: Kaedah Perolehan Tahun 2012
Table 9: Types of Medicines Procurement in 2012
2. Formulari Ubat KKM
MOH Drug Formulary
Rajah 1: Penyenaraian Ubat dalam Formulari Ubat (2001-2012)
Figure 1: Drugs Listed into MOH Drug Formulary (2001-2012)
Pada tahun 2012, 3 ubat telah dikeluarkan daripada formulari manakala 51 ubat baru termasuk
kekuatan atau formulasi baru telah disenaraikan dalam formulari ubat KKM. Ini menjadikan
keseluruhan ubat dalam Formulari Ubat KKM berjumlah 1578 pada akhir tahun 2012 (Rajah 1).
In 2012, 3 drugs have been removed from the formulary while 51 drugs, including new formulations or
strengths, were listed into the formulary. As a result, there were a total of 1578 preparations in the
MOH Drug Formulary at the end of 2012 (Figure 1).
Tahun
Year
APPL
(RM)
KKM Kontrak
MOH Contract
(RM)
Pembelian Terus & Sebutharga
Local Purchase & Quotation
(RM)
2012 810,332,787 (41%) 760,829,333 (38%)
412,355,654 (21%)
2. Formulari Ubat KKM MOH Drug Formulary
3. Dasar dan Perundangan Workshops and Legal Framework
Bengkel Kajian Penuh Dasar Ubat Nasional (DUNas)Full Term Review of Malaysia National Medicines Policy Workshop (MNMP)
Bengkel Kajian Penuh Dasar Ubat Nasional (DUNas) telah diadakan pada 15-17 Oktober 2012 di Holiday Villa Hotel & Suites, Subang, Selangor. Objektif bengkel ini diadakan adalah untuk menilai semula pencapaian, kelemahan dan kesesuaian strategi yang telah dilaksanakan sejak tahun 2006 - 2012 serta mencadangkan komponen dan strategi baru bagi 5 tahun akan datang. Bengkel ini melibatkan semua pihak yang berkepentingan memandangkan input dan persetujuan semua pihak adalah penting bagi menggubal dasar yang akan menentukan hala tuju sektor farmaseutikal pada tahun-tahun akan datang. Seramai 150 peserta dari pelbagai badan profesional, persatuan-persatuan pengguna dari industri yang berkaitan, agensi-agensi kerajaan dan kementerian serta universiti telah menghadiri bengkel ini.
Pada tahun 2012, 3 ubat telah dikeluarkan daripada formulari manakala 51 ubat baru termasuk kekuatan atau formulasi baru telah disenaraikan dalam formulari ubat KKM. Ini menjadikan keseluruhan ubat dalam Formulari Ubat KKM berjumlah 1578 pada akhir tahun 2012 (Rajah 1).
In 2012, 3 drugs have been removed from the formulary while 51 drugs, including new formulations or strengths, were listed into the formulary. As a result, there were a total of 1578 preparations in the MOH Drug Formulary at the end of 2012 (Figure 1).
16 PROGRAM FARMASI / PHARMACY PROGRAMME
LAPORAN TAHUNANANNUAL REPORT2012
Intipati dasar sedia ada yang memberi penekanan kepada komponen kualiti dan keselamatan ubat, akses kepada ubat serta kemampuan mendapat ubat-ubatan telah dipersetujui oleh semua pihak untuk dikekalkan. Isu-isu baru seperti Governance of Medicine serta daya maju dan kemampanan industri farmaseutikal telah dimasukkan ke dalam dasar yang telah disemak semula. Perkongsian dan kerjasama bagi industri penjagaan kesihatan telah dilihat dalam konteks yang lebih makro di mana ia perlu direalisasikan dalam bidang pembangunan sumber manusia, penyelidikan dan pembangunan dan kerjasama teknikal. Perkara lain yang turut diberi perhatian ialah pembangunan dan pelaksanaan amalan-amalan terbaik untuk memastikan penyediaan ubat-ubatan yang berkualiti diimplikasikan di semua peringkat penjagaan kesihatan. Komitmen yang diberikan oleh semua pihak berkepentingan dari sektor awam dan swasta dalam proses penilaian semula telah berjaya menghasilkan Draf DUNas Semakan I. Beberapa bengkel susulan akan dijalankan untuk merangka pelan tindakan bagi 5 tahun seterusnya.
The Pharmaceutical Services Division, Ministry of Health Malaysia held a workshop on the Full Term Review of the Malaysian National Medicines Policy (MNMP) in Holiday Villa & Suites, Subang, Selangor on 15-17 October 2012. The objectives of the workshop were to review on the achievements, shortfalls and relevance of the present strategies which were implemented from end of 2006 – 2012 and to propose new components and strategies for the next 5 years. The workshop involved all stakeholders as their inputs and consensuses are valuable towards the formulation of the policy which we chart the journey for the pharmaceutical sector in the coming years. The workshop was attended by 150 participants from various professional bodies, relevant industry consumer associations, other government agencies and ministries as well as universities.
The essence of the current policy which emphasizes on quality and safety, accessibility and affordability is maintained and agreed upon by all the stakeholders. New issues that are considered pertinent such as the governance of medicines and viability and sustainability of the pharmaceutical industry are regarded as important and therefore included in the revised policy. Partnership and collaboration for the healthcare industry was viewed in a more macro context whereby it should be realised in areas of human resource, research and development and technical cooperation. Another area that needs focus is the development and implementation of best practices to ensure the provision of quality medicines use at all levels of health care. The stakeholders also highlighted that systematic consideration of the practical aspects of implementation is also pertinent to the successful implementation of the policy. The output of the workshop was a draft of the revised policy. Several follow-up workshops will be conducted to fine tune the policy and to formulate the next 5-year plan of action.
17PROGRAM FARMASI / PHARMACY PROGRAMME
LAPORAN TAHUNANANNUAL REPORT 2012
12 | L a p o r a n T a h u n a n 2 0 1 2
The essence of the current policy which emphasizes on quality and safety, accessibility and
affordability is maintained and agreed upon by all the stakeholders. New issues that are considered
pertinent such as the governance of medicines and viability and sustainability of the pharmaceutical
industry are regarded as important and therefore included in the revised policy. Partnership and
collaboration for the healthcare industry was viewed in a more macro context whereby it should be
realised in areas of human resource, research and development and technical cooperation. Another
area that needs focus is the development and implementation of best practices to ensure the provision
of quality medicines use at all levels of health care. The stakeholders also highlighted that systematic
consideration of the practical aspects of implementation is also pertinent to the successful
implementation of the policy. The output of the workshop was a draft of the revised policy. Several
follow-up workshops will be conducted to fine tune the policy and to formulate the next 5-year plan of
action.
Rajah 2 : Upacara Perasmian Bengkel Kajian Penuh DUNas
Figure 2: Official Launching of DUNas Workshop
13 | L a p o r a n T a h u n a n 2 0 1 2
Rajah 3 : Peserta-Peserta DUNas
Figure 3: DUNas Participants
Rang Undang-Undang Farmasi (RUUF)
New Pharmacy Bill
Bahagian Perkhidmatan Farmasi (BPF) telah bersetuju untuk menggabungkan Akta Pendaftaran Ahli
Farmasi 1951, Akta Racun 1952, Akta Jualan Dadah 1952 dan Akta Ubat (Iklan dan Penjualan) 1956
dalam satu Undang-Undang yang baru. Justeru itu, Rang Undang-Undang Farmasi yang baru (RUUF)
telah digubal untuk mengatasi kelemahan dan lakuna dalam undang-undang yang sedia ada; untuk
mengalakkan keharmonian berpandu dan liberalisasi di kalangan peserta industri; untuk
mengesamengesahkan perjanjian antarabangsa dan konvensyen yang telah ditandatangani oleh
kerajaan; untuk mengenakan hukuman ke atas kesalahan serius dan memperkukuhkan struktur dan
kuasa pihak berkuasa dan peranan pegawai-pegawai penguat kuasa.
BPF telah melaksanakan seranta awam atas talian untuk memastikan ketelusan dan penerimaan
Rang Undang-Undang Farmasi kepada orang ramai termasuk stakeholders. Seranta awam atas talian
tersebut telah dipaparkan di portal KKM dari 16 November 2012 sehingga 7 Disember 2012.
Keputusan daripada seranta awam atas talian tersebut, sebanyak 548 maklumbalas telah diperolehi.
92.67% maklum balas tersebut adalah daripada ahli farmasi swasta; 2.56% daripada ahli farmasi KKM
dan selebihnya adalah dari ahli akademik (0.55%), pengamal perubatan (0.18%), penolong pegawai
farmasi (0.37%), penolong pegawai perubatan (0.18%), NGOs (1.65%), orang ramai (0.18%), industri
(0.18%), pengamal perubatan tradisional (0.92%), kedutaan-kedutaan asing (0.18%) dan agensi-
agensi di bawah KKM (0.37%). Hanya 1.28% membantah pembentangan Rang Undang-Undang
Farmasi tersebut di parlimen.
18 PROGRAM FARMASI / PHARMACY PROGRAMME
LAPORAN TAHUNANANNUAL REPORT2012
Rang Undang-Undang Farmasi (RUUF) New Pharmacy Bill
Bahagian Perkhidmatan Farmasi (BPF) telah bersetuju untuk menggabungkan Akta Pendaftaran Ahli Farmasi 1951, Akta Racun 1952, Akta Jualan Dadah 1952 dan Akta Ubat (Iklan dan Penjualan) 1956 dalam satu Undang-Undang yang baru. Justeru itu, Rang Undang-Undang Farmasi yang baru (RUUF) telah digubal untuk mengatasi kelemahan dan lakuna dalam undang-undang yang sedia ada; untuk mengalakkan keharmonian berpandu dan liberalisasi di kalangan peserta industri; untuk mengesahkan perjanjian antarabangsa dan konvensyen yang telah ditandatangani oleh kerajaan; untuk mengenakan hukuman ke atas kesalahan serius dan memperkukuhkan struktur dan kuasa pihak berkuasa dan peranan pegawai-pegawai penguat kuasa.
BPF telah melaksanakan seranta awam atas talian untuk memastikan ketelusan dan penerimaan Rang Undang-Undang Farmasi kepada orang ramai termasuk stakeholders. Seranta awam atas talian tersebut telah dipaparkan di portal KKM dari 16 November 2012 sehingga 7 Disember 2012. Keputusan daripada seranta awam atas talian tersebut, sebanyak 548 maklumbalas telah diperolehi. 92.67% maklum balas tersebut adalah daripada ahli farmasi swasta; 2.56% daripada ahli farmasi KKM dan selebihnya adalah dari ahli akademik (0.55%), pengamal perubatan (0.18%), penolong pegawai farmasi (0.37%), penolong pegawai perubatan (0.18%), NGOs (1.65%), orang ramai (0.18%), industri (0.18%), pengamal perubatan tradisional (0.92%), kedutaan-kedutaan asing (0.18%) dan agensi-agensi di bawah KKM (0.37%). Hanya 1.28% membantah pembentangan Rang Undang-Undang Farmasi tersebut di parlimen.
The Pharmaceutical Services Division (PSD) has made the decision to formulate a new law that incorporates the Registration of Pharmacists Act 1951, Poisons Act 1952, Sale of Drugs Act 1952 and the Medicines (Advertisement and Sale) Act 1956 into a new Act. Subsequently, the Pharmacy Bill was drafted, among others, to overcome weaknesses and lacuna in existing legislation; to promote the guided harmonization and liberalization among industry players; to ratify international treaties and conventions which were signed by the state; to impose deterrent penalties on serious offences and to strengthen the structure and power of the competent authority and clarify the role of enforcement officers.
The PSD has implemented an online public engagement to ensure that the Pharmacy Bill is transparent and to engage with the public and other stakeholders. This is a channel to announce and acquire feedback from them. Extracts of the Pharmacy Bill was displayed in the MOH Portal on 16th November 2012 until 7th December 2012. As a result of the online public engagement, a total of 548 feedbacks were received. The respondents were from private pharmacists (92.67%) and 2.56% were from pharmacists in the MOH while the rest were from academia (0.55%), medical practitioners (0.18%), pharmacy assistants (0.37%), medical assistants (0.18%), NGOs (1.65%), public (0.18%), industry (0.18%), traditional medicine practitioners (0.92%), foreign embassies (0.18%) and agencies in the Ministry of Health (0.37%). Only 1.28% of the respondents had protested the tabling of the Bill in the Parliament.
19PROGRAM FARMASI / PHARMACY PROGRAMME
LAPORAN TAHUNANANNUAL REPORT 2012
4. Persidangan Conferences
Persidangan Perkembangan dan Kajian Farmasi ke-7 20127th Pharmacy R&D Conference 2012
Persidangan ini telah diadakan pada 19-21 Jun 2012 di The Zon Regency Hotel, Johor Bahru. Peserta terdiri daripada ahli farmasi dari KKM, Kementerian Pertahanan, Hospital Universiti dan agensi-agensi awam dan swasta yang lain. Objektif utama persidangan tersebut adalah untuk menggalakkan, mewujudkan wadah untuk berkongsi hasil penyelidikan di kalangan peserta.
This conference was held on 19th to 21st June 2012 at The Zon Regency Hotel, Johor Bahru. Participants were pharmacist, healthcare personnel from Ministry of Health, Ministry of Defense, University Hospitals and other public and private agencies. The conference was to encourage and create a platform to share research findings among the participants.
15 | L a p o r a n T a h u n a n 2 0 1 2
Rajah 4 : Upacara Perasmian Persidangan Perkembangan dan Kajian Farmasi ke-7 2012
Figure 4 :Official Launching of 7th Pharmacy R&D Conference 2012
Rajah 5 : Peserta menjelaskan penyelidikan kepada mantan Ketua Pengarah Kesihatan (KPK)
Figure 5: Briefing of Ex-Director General of Health by Participant
Pharmacy Practice Scientific Conference
Pharmacy Practice Scientific Conference (PPSC) telah diadakan pada 24 - 25 Mac 2012 di Hotel
Istana, Kuala Lumpur dengan tema : Pharmacy Specialization: Achieving Excellence. Sehubungan itu,
empat orang ahli farmasi yang mempunyai kepakaran dalam pelbagai bidang dari Amerika Syarikat
telah dijemput untuk menjayakan bengkel persediaan menghadapi peperiksaan Board of Pharmacy
Specialties. Seramai 17 orang Pegawai Farmasi KKM telah lulus di dalam peperiksaan tersebut yang
dikendalikan oleh American College of Clinical Pharmacy.
15 | L a p o r a n T a h u n a n 2 0 1 2
Rajah 4 : Upacara Perasmian Persidangan Perkembangan dan Kajian Farmasi ke-7 2012
Figure 4 :Official Launching of 7th Pharmacy R&D Conference 2012
Rajah 5 : Peserta menjelaskan penyelidikan kepada mantan Ketua Pengarah Kesihatan (KPK)
Figure 5: Briefing of Ex-Director General of Health by Participant
Pharmacy Practice Scientific Conference
Pharmacy Practice Scientific Conference (PPSC) telah diadakan pada 24 - 25 Mac 2012 di Hotel
Istana, Kuala Lumpur dengan tema : Pharmacy Specialization: Achieving Excellence. Sehubungan itu,
empat orang ahli farmasi yang mempunyai kepakaran dalam pelbagai bidang dari Amerika Syarikat
telah dijemput untuk menjayakan bengkel persediaan menghadapi peperiksaan Board of Pharmacy
Specialties. Seramai 17 orang Pegawai Farmasi KKM telah lulus di dalam peperiksaan tersebut yang
dikendalikan oleh American College of Clinical Pharmacy.
20 PROGRAM FARMASI / PHARMACY PROGRAMME
LAPORAN TAHUNANANNUAL REPORT2012
16 | L a p o r a n T a h u n a n 2 0 1 2
The Pharmacy Practice Scientific Conference (PPSC) was held on the 24th-25
th March 2012 at Hotel
Istana, Kuala Lumpur with the theme of Pharmacy Specializations: Achieving Excellence. In tandem
with the theme of the conference, 4 specialist pharmacists from the United States of America were
invited to assist the preparation workshop for the Board of Pharmacy Specialists Examination. A total
of 17 MOH pharmacists have passed the exam that was organized by the American College of Clinical
Pharmacy.
5. Pelancaran Program Duta Kenali Ubat Anda
Official Launching of Know Your Medicine Ambassador
Programme
Program ini telah dilancarkan pada 11 Mei 2012 di Kota Bharu, Kelantan. Di antara objektif program
yang telah dijalankan ini adalah untuk menggalakkan penglibatan aktif pengguna di dalam aktiviti
penggunaan ubat berkualiti, meningkatkan pengetahuan dan kemahiran pengguna agar mereka
mampu membuat keputusan berkenaan penjagaan kesihatan mereka, penerapan konsep
empowerment di dalam pengubatan di kalangan masyarakat Malaysia dan juga untuk membentuk
rangkaian individu di dalam komuniti yang bertindak sebagai wakil kesihatan masyarakat yang
menyokong penggunaan ubat secara berkualiti.
This programme was launched on 11th of May 2012 in Kota Bharu, Kelantan. Among the objectives of
the programme were to promote quality use of medicines among consumers, increasing consumer
knowledge and skills so that they can make decisions about their health care, incorporate the concept
of empowerment in medication and also to form network of individuals in the community who act as
representatives that support quality use of medicines.
Rajah 6: Modul Program Rajah 7: Majlis Pelancaran Figure 6: Programme Module Figure 7: Official Launching
Pharmacy Practice Scientific Conference
Pharmacy Practice Scientific Conference (PPSC) telah diadakan pada 24 - 25 Mac 2012 di Hotel Istana, Kuala Lumpur dengan tema : Pharmacy Specialization: Achieving Excellence. Sehubungan itu, empat orang ahli farmasi yang mempunyai kepakaran dalam pelbagai bidang dari Amerika Syarikat telah dijemput untuk menjayakan bengkel persediaan menghadapi peperiksaan Board of Pharmacy Specialties. Seramai 17 orang Pegawai Farmasi KKM telah lulus di dalam peperiksaan tersebut yang dikendalikan oleh American College of Clinical Pharmacy.
The Pharmacy Practice Scientific Conference (PPSC) was held on the 24th-25th March 2012 at Hotel Istana, Kuala Lumpur with the theme of Pharmacy Specializations: Achieving Excellence. In tandem with the theme of the conference, 4 specialist pharmacists from the United States of America were invited to assist the preparation workshop for the Board of Pharmacy Specialists Examination. A total of 17 MOH pharmacists have passed the exam that was organized by the American College of Clinical Pharmacy.
5. Pelancaran Program Duta Kenali Ubat Anda Official Launching of Know Your Medicine Ambassador Programme
Program ini telah dilancarkan pada 11 Mei 2012 di Kota Bharu, Kelantan. Di antara objektif program yang telah dijalankan ini adalah untuk menggalakkan penglibatan aktif pengguna di dalam aktiviti penggunaan ubat berkualiti, meningkatkan pengetahuan dan kemahiran pengguna agar mereka mampu membuat keputusan berkenaan penjagaan kesihatan mereka, penerapan konsep empowerment di dalam pengubatan di kalangan masyarakat Malaysia dan juga untuk membentuk rangkaian individu di dalam komuniti yang bertindak sebagai wakil kesihatan masyarakat yang menyokong penggunaan ubat secara berkualiti.
This programme was launched on 11th of May 2012 in Kota Bharu, Kelantan. Among the objectives of the programme were to promote quality use of medicines among consumers, increasing consumer knowledge and skills so that they can make decisions about their health care, incorporate the concept of empowerment in medication and also to form network of individuals in the community who act as representatives that support quality use of medicines.
21PROGRAM FARMASI / PHARMACY PROGRAMME
LAPORAN TAHUNANANNUAL REPORT 2012
6. Penerbitan Bahagian Perkhidmatan Farmasi Pharmaceutical Services Division Publications
Antara penerbitan yang telah dikeluarkan dan diedarkan sepanjang tahun 2012 di fasiliti KKM adalah 3 protokol, 2 flipchart, 4 risalah dan 15 garis panduan.
Sebanyak 3 edisi Berita Ubat-Ubatan (majalah mengenai polisi PBKD), 3 edisi Buletin MADRAC (Malaysian Adverse Drug Reactions Advisory Committee) dan satu naskah Laporan Tahunan BPFK telah diterbitkan untuk edaran pada tahun 2012.
Among the publications that were produced and circulated throughout MOH facilities in the year 2012 were 3 protocols, 2 flipcharts, 4 pamphlets and 15 guidelines.
A total of 3 editions of Berita Ubat-Ubatan (magazine concerning DCA policies) and 3 editions of the MADCRAC Bulletin (Malaysian Adverse Drug Reactions Advisory Committee Bulletin) were published in the year 2012, along with one edition of the NPCB Annual report.
17 | L a p o r a n T a h u n a n 2 0 1 2
6. Penerbitan Bahagian Perkhidmatan Farmasi Pharmaceutical Services Division Publications Antara penerbitan yang telah dikeluarkan dan diedarkan sepanjang tahun 2012 di fasiliti KKM adalah 3
protokol, 2 flipchart, 4 risalah dan 15 garis panduan.
Sebanyak 3 edisi Berita Ubat-‐Ubatan (majalah mengenai polisi PBKD), 3 edisi Buletin MADRAC
(Malaysian Adverse Drug Reactions Advisory Committee) dan satu naskah Laporan Tahunan BPFK
telah diterbitkan untuk edaran pada tahun 2012.
Among the publications that were produced and circulated throughout MOH facilities in the year 2012
were 3 protocols, 2 flipcharts, 4 pamphlets and 15 guidelines.
A total of 3 editions of Berita Ubat-Ubatan (magazine concerning DCA policies) and 3 editions of the
MADCRAC Bulletin (Malaysian Adverse Drug Reactions Advisory Committee Bulletin) were published
in the year 2012, along with one edition of the NPCB Annual report.
Jadual 10: Jenis Penerbitan Yang Dikeluarkan
Table 10: Types of Publications Produced
Bil. No.
Jenis Penerbitan
Type of Publication
Tajuk Penerbitan Title of Publication
1 Protokol Protocol
Home Medication Review Protocol Buku Rawatan Antikoagulasi (Warfarin) Anticoagulation Treatment Book (Warfarin) Protokol Medication Therapy Adherence Clinic: Psikiatri
2 Flipchart
Modul Pendidikan Pesakit bagi perkhidmatan DMTAC Patient Education Module for DMTAC Service Kaunseling pesakit HIV/AIDS Counselling HIV/AIDS Patients
3 Risalah
Pamphlet
Memahami jangkitan HIV Understanding HIV Infection Memahami ubat Anti Retroviral (HAART) Understanding Anti-‐Retroviral Medications (HAART)
Kalendar Bermesej Messages Calendar
What Prescribers Should Know About Generic Medicines
22 PROGRAM FARMASI / PHARMACY PROGRAMME
LAPORAN TAHUNANANNUAL REPORT2012
18 | L a p o r a n T a h u n a n 2 0 1 2
4
Garis Panduan &
Modul latihan Guidelines & Training Modules
Modul latihan Medication Therapy Adherence Clinic (MTAC) Warfarin Medication Therapy Adherence Clinic (MTAC) Warfarin Training Module Modul latihan Wad Farmasi Ward Pharmacy Training Module Modul latihan Respiratory MTAC In Adult Asthma & COPD Pharmacist Training Module for Respiratory MTAC In Adult Asthma & COPD Modul latihan Parenteral Nutrition 1st Edition Pharmacist Training Module Parenteral Nutrition 1st Edition Pharmacist Training Logbook Medication Therapy Adherence Clinic (MTAC): Diabetes Mellitus Modul Program Kenali Duta Ubat Anda Know Your Medicine Ambassador Program Module Garis panduan kaunseling ubat-‐ubatan Counselling Guidelines of Medicines Garis panduan Pemeriksaan Premis Guidelines on Premises Inspection Cross Reference for Export-‐Controlled Chemicals Garis panduan Penggendalian Aduan Guidelines on Handling Complaints Garis panduan Siasatan untuk Pegawai Penguatkuasa Farmasi, Kementerian Kesihatan Malaysia Investigation Guidelines for Enforcement Officers, Ministry of Health Garis panduan Pelupusan Barang Rampasan/ Ekshibit Guidelines on Disposal of Confiscated Goods/ Exhibits Garis panduan Menutup Kertas Siasatan Tanpa Tindakan Lanjut Guidelines on Closing Investigation Papers without Further Action Garis panduan Pengendalian Ekshibit dan Stor Ekshibit Cawangan Penguatkuasaan Farmasi, Kementerian Kesihatan Malaysia Guidelines on Handling Exhibits and Exhibits Store for Enforcement Pharmacy, Ministry of Health Kompilasi Contoh-‐Contoh Pertuduhan bagi Akta Racun 1952, Akta Jualan Dadah 1952 dan Akta Pendaftaran Ahli Farmasi 1951 Compilation of example of charges of Poisons Act 1952, Sale of Drugs Act 1952 and Registration of Pharmacists Act 1951
23PROGRAM FARMASI / PHARMACY PROGRAMME
LAPORAN TAHUNANANNUAL REPORT 2012
Data bagi Senarai Harga Ubat 2012 telah disediakan untuk penerbitan pada Disember 2012. Senarai harga ubat-ubatan ini boleh diakses dengan mudah oleh orang ramai di laman web rasmi BPF (www.pharmacy.gov.my).
Unit Proforma telah menyediakan garis panduan sebagai rujukan kepada semua fasiliti KKM dalam menggunakan ubat-ubatan yang terdapat di dalam dan juga di luar FUKKM. Antara kandungan yang terdapat di dalam garis panduan ini adalah:
i. Prosedur penyenaraian ubat ke dalam FUKKMii. Pengenalan terhadap Senarai Ubat Penting Kebangsaan atau National Essential Drug List
(NEDL), sekarang dikenali sebagai National Essential Medicines List (NEML)iii. Prosedur permohonan ubat khas Ketua Pengarah Kesihatan (KPK) dan Pengarah Kanan
Perkhidmatan Farmasi (PKPF)iv. Borang proforma dan KPKv. Terma rujukan Jawatankuasa Kerja Ubat di peringkat kesihatan, hospital dan negeri.
Buku garis panduan ini telah diedarkan kepada semua fasiliti KKM di seluruh negara.
The Medicines Price List of 2012 data was made available for publication by December 2012. This list can be easily accessed through the official PSD website. (www.pharmacy.gov.my)
The Proforma Unit has prepared a guideline as reference to all MOH facilities in using medicines listed in and out of the Formulary. Among the contents of the guidelines are:
i. Procedure in listing a medicines into the MOH medicines formularyii. Introduction to the National Essential Drug List (NEDL), now known as National Essential
Medicines List (NEML)iii. Procedure for aplication of special approval medicines by the Director General of Health
and Senior Director of Pharmaceutical Services Divisioniv. Proforma and special approval medicines formsv. Terms of reference for the Therapeutic Drug Working Committee in the health, hospital and
state.
This guideline has been circulated to all the MOH facilities in the country.
20 | L a p o r a n T a h u n a n 2 0 1 2
Rajah 8 : Senarai Harga Ubat yang Dikeluarkan pada Tahun 2012 (Cetakan 2013)
Figure 8 : Medicines Price List (Printed 2013)
7. KAJIAN PENGGUNAAN UBAT KEBANGSAAN
NATIONAL MEDICINES USE SURVEY
Projek Kajian Penggunaan Ubat Kebangsaan (NMUS) telah dimulakan pada tahun 2005 oleh Pusat
Penyelidikan Klinikal (CRC) dengan kerjasama Bahagian Perkhidmatan Farmasi (BPF). Mulai bulan
September 2006, pengurusan NMUS telah diambil alih oleh BPF manakala CRC mengendalikan
aspek pelaksanaan kajian dan khidmat statistik. NMUS dilaksanakan secara berterusan bagi mengkaji
penggunaan ubat-ubatan di negara ini yang dijangka berubah mengikut masa. Berikut merupakan
objektif NMUS:
i. Untuk mengetahui jenis dan jumlah ubat-ubat yang dibekalkan di Malaysia. Ini penting untuk
mengukur tahap penggunaan dan perbelanjaan ubat-ubatan di negara ini.
ii. Untuk mengetahui jenis dan jumlah ubat-ubatan yang dipreskrib dan/atau didispen di
Malaysia. Ia penting untuk mengetahui kualiti preskripsi dan amalan pendispensan di negara
ini.
iii. Untuk mengetahui jenis dan jumlah ubat-ubatan yang digunakan oleh pengguna-pengguna di
Malaysia. Ia penting untuk mengukur pola penggunaan ubat-ubatan bagi tujuan menilai
penggunaan ubat secara rasional oleh pengguna di dalam negara ini.
iv. Untuk menggalakkan dan memudahkan kajian berkaitan penggunaan ubat-ubatan.
Bagi memperolehi data di pelbagai peringkat sistem pembekalan dan pengedaran ubat di negara ini
(termasuk fasiliti kesihatan awam dan swasta), NMUS perlu menjalankan beberapa kajian secara
sistematik. Data telah dikumpul dengan menggunakan kaedah-kaedah berikut:
24 PROGRAM FARMASI / PHARMACY PROGRAMME
LAPORAN TAHUNANANNUAL REPORT2012
7. KAJIAN PENGGUNAAN UBAT KEBANGSAAN NATIONAL MEDICINES USE SURVEY
Projek Kajian Penggunaan Ubat Kebangsaan (NMUS) telah dimulakan pada tahun 2005 oleh Pusat Penyelidikan Klinikal (CRC) dengan kerjasama Bahagian Perkhidmatan Farmasi (BPF). Mulai bulan September 2006, pengurusan NMUS telah diambil alih oleh BPF manakala CRC mengendalikan aspek pelaksanaan kajian dan khidmat statistik. NMUS dilaksanakan secara berterusan bagi mengkaji penggunaan ubat-ubatan di negara ini yang dijangka berubah mengikut masa. Berikut merupakan objektif NMUS:
• Untuk mengetahui jenis dan jumlah ubat-ubat yang dibekalkan di Malaysia. Ini penting untuk mengukur tahap penggunaan dan perbelanjaan ubat-ubatan di negara ini.
• Untuk mengetahui jenis dan jumlah ubat-ubatan yang dipreskrib dan/atau didispen di Malaysia. Ia penting untuk mengetahui kualiti preskripsi dan amalan pendispensan di negara ini.
• Untuk mengetahui jenis dan jumlah ubat-ubatan yang digunakan oleh pengguna-pengguna di Malaysia. Ia penting untuk mengukur pola penggunaan ubat-ubatan bagi tujuan menilai penggunaan ubat secara rasional oleh pengguna di dalam negara ini.
• Untuk menggalakkan dan memudahkan kajian berkaitan penggunaan ubat-ubatan.
Bagi memperolehi data di pelbagai peringkat sistem pembekalan dan pengedaran ubat di negara ini (termasuk fasiliti kesihatan awam dan swasta), NMUS perlu menjalankan beberapa kajian secara sistematik. Data telah dikumpul dengan menggunakan kaedah-kaedah berikut:
• Muat turun daripada pangkalan data sedia ada seperti pangkalan data perolehan ubat-ubatan hospital
• Pengutipan data primer untuk kajian pendispensan
Pencapaian NMUS pada tahun 2012 adalah seperti di Jadual 11. Hasil pelaksanaan NMUS, lima laporan Malaysian Statistics on Medicines (MSOM) telah berjaya diterbitkan, bagi tahun 2004 hingga 2008 yang boleh dicapai melalui laman web BPF (www.pharmacy.gov.my) dan CRC (www.crc.gov.my). Penerbitan Laporan MSOM 2009 dan 2010 akan diterbitkan pada awal tahun 2014.
Laporan-laporan yang dijana amat berguna dalam menyediakan data awal berkaitan penggunaan ubat-ubatan di negara ini dan boleh dijadikan sebagai asas untuk tindakan lanjut apabila diperlukan. Sebagai contoh, ia boleh digunakan bagi membuat keputusan yang lebih baik dalam menggunakan peruntukan sumber-sumber untuk penjagaan kesihatan di Malaysia. Data ini juga boleh digunakan untuk membandingkan corak penggunaan ubat-ubatan di Malaysia dengan negara-negara maju. Ia penting bagi memantau seterusnya meningkatkan kualiti penggunaan ubat ke arah rawatan yang lebih kos-efektif selaras dengan objektif Dasar Ubat Nasional (DUNas).
25PROGRAM FARMASI / PHARMACY PROGRAMME
LAPORAN TAHUNANANNUAL REPORT 2012
The National Medicines Use Survey (NMUS) which was initiated in 2005 is a research project jointly sponsored by the Pharmaceutical Services Division (PSD) and Clinical Research Centre (CRC). From the beginning of September 2006, PSD undertook the role of the primary sponsor for the NMUS while CRC remained as an important collaborating unit that provides research and statistical support. NMUS is conducted continuously to study the utilization of medicines in the country which is expected to change over time. The objectives of NMUS are:
• To know the types and amount of medicines supplied in Malaysia. These are useful in measuring the utilization and the expenditure level of medicines in the country.
• To know the types and amount of medicines prescribed and/or dispensed in Malaysia. These are useful measures for the quality of prescription and dispensing practices in the country.
• To know the types and amount of medicines consumed by consumers in Malaysia. These are useful measures for the pattern of use of medicines in order to evaluate its rational use by consumers in the country.
• To stimulate and facilitate researches on use of medicines.
In order to capture data at various levels of the medicines supply and distribution system in the country (including government and private healthcare facilities), NMUS has to conduct several surveys systemically. The following methods are used to collect these data:
• Download from existing databases, for example hospital’s pharmaceutical procurement databases
• Primary data collection for dispensing survey • The achievements of NMUS for the year 2012 are summarized in Table 11. As a
result of the implementation of NMUS, four reports entitled Malaysian Statistics on Medicines (MSOM) have been published for the year 2004 until 2008, which are accessible through the websites of PSD (www.pharmacy.gov.my) and CRC (www.crc.gov.my). The report for MSOM 2009 and 2010 will be published in early 2014.
These generated reports have been useful in providing preliminary data on medicines use in the country and can be used as a basis for further actions, if necessary. For example, it can be used as a tool for better decision making in the allocation of healthcare resources for the Malaysian population. These data can also be used for comparison on drug usage pattern with developed countries. This effort is important for monitoring to increase the quality of drug usage towards a more cost effective treatment. This is in accordance with the objectives of the Malaysian National Medicines Policy (NMP).
26 PROGRAM FARMASI / PHARMACY PROGRAMME
LAPORAN TAHUNANANNUAL REPORT2012
22 | L a p o r a n T a h u n a n 2 0 1 2
iii. The achievements of NMUS for the year 2012 are summarized in Table 11. As a result of the
implementation of NMUS, four reports entitled Malaysian Statistics on Medicines (MSOM)
have been published for the year 2004 until 2008, which are accessible through the websites
of PSD (www.pharmacy.gov.my) and CRC (www.crc.gov.my). The report for MSOM 2009 and
2010 will be published in early 2014.
These generated reports have been useful in providing preliminary data on medicines use in the
country and can be used as a basis for further actions, if necessary. For example, it can be used as a
tool for better decision making in the allocation of healthcare resources for the Malaysian population.
These data can also be used for comparison on drug usage pattern with developed countries. This
effort is important for monitoring to increase the quality of drug usage towards a more cost effective
treatment. This is in accordance with the objectives of the Malaysian National Medicines Policy (NMP).
Rajah 9 : Peserta-peserta NMUS Rajah 10 : Laporan MSOM
Figure 9: NMUS Participants Figure 10: MSOM Report
23 | L a p o r a n T a h u n a n 2 0 1 2
Jadual 11: Pencapaian NMUS dalam Tahun 2012
Table 11: Achievement of NMUS in 2012
Bil.
No.
Aktiviti
Activities
Output
Output
Pencapaian
Achievements
1.
Pelaksanaan berterusan projek NMUS dengan usaha sama CRC.
Continuous implementation of NMUS project in collaboration with CRC.
Penerbitan Malaysian Statistics on Medicines (MSOM).
Publication of the Malaysian Statistics on Medicines (MSOM).
MSOM 2008:
Telah diterbitkan pada Mei 2013.
MSOM 2008:
Published in May 2013.
2. Pembangunan aplikasi client-server untuk kemasukan data pendispensan ubat. Development of a client-server application to enter dispensing data.
Aplikasi “NMUS Data Entry (Retail Pharmacy)”. “NMUS Data Entry (Retail Pharmacy)” Application.
1 aplikasi.
1 application.
8. Aktiviti Pembangunan Sistem System Development Activities Sepanjang tahun 2012, Bahagian Perkhidmatan Farmasi, KKM telah menitikberatkan pembangunan
Sistem Maklumat Farmasi Hospital (PhIS) dan sistem maklumat farmasi klinik (CPS). Projek ini memberi
tumpuan kepada aktiviti pembangunan 12 modul dalam sistem dan pencapaian sehingga 31 Disember
2012 adalah seperti di Jadual 12.
Sebanyak 14 aktiviti seperti bengkel penyediaan, semakan, lawatan dan mesyuarat telah diadakan
bagi mengesahkan keperluan pengguna sebelum dokumen User Requirement Specification (URS)
dan System Design Documentation (SDD) dimuktamadkan.
Selain pembangunan sistem, aktiviti persediaan pelaksanaan di fasiliti perintis telah dijalankan dengan
pesatnya seperti di Jadual 13. Ini bagi memastikan setiap fasiliti bersedia dari segi infrastruktur dan
pengguna ke arah melaksanakan sistem ini di fasiliti masing-masing.
27PROGRAM FARMASI / PHARMACY PROGRAMME
LAPORAN TAHUNANANNUAL REPORT 2012
8. Aktiviti Pembangunan Sistem System Development Activities
Sepanjang tahun 2012, Bahagian Perkhidmatan Farmasi, KKM telah menitikberatkan pembangunan Sistem Maklumat Farmasi Hospital (PhIS) dan sistem maklumat farmasi klinik (CPS). Projek ini memberi tumpuan kepada aktiviti pembangunan 12 modul dalam sistem dan pencapaian sehingga 31 Disember 2012 adalah seperti di Jadual 12.
Sebanyak 14 aktiviti seperti bengkel penyediaan, semakan, lawatan dan mesyuarat telah diadakan bagi mengesahkan keperluan pengguna sebelum dokumen User Requirement Specification (URS) dan System Design Documentation (SDD) dimuktamadkan.
Selain pembangunan sistem, aktiviti persediaan pelaksanaan di fasiliti perintis telah dijalankan dengan pesatnya seperti di Jadual 13. Ini bagi memastikan setiap fasiliti bersedia dari segi infrastruktur dan pengguna ke arah melaksanakan sistem ini di fasiliti masing-masing.
Peruntukan perkakasan telah dimuktamadkan semasa mesyuarat pelaksanaan infrastruktur di fasiliti perintis. Selain itu pengguna juga diperkenalkan dengan konsep ADKAR (Awareness, Desire, Knowledge, Ability, Reinforcement) semasa Program Pengurusan Perubahan dijalankan.
In 2012, PSD has emphasized on the importance of the development of the Pharmacy Hospital Information System (PHIS) and the Clinical Pharmacy Information System (CPS). This project focused on the development of 12 modules in the system throughout the year 2012. Achievements of system development until 31 December 2012 are shown in Table 12.
A total of 14 activities such as workshops, reviews, visits and meetings were held to validate and verify the user requirements before finalizing the User Requirement Specification (URS) document and System Design Documentation (SDD).
Besides system development, implementation readiness and preparation activities were conducted extensively at pilot facilities as shown in Table 13. This is to ensure that all facilities have adequate infrastructure ensure and user-readiness towards implementing the system in their facilities.
Allocation of hardware was finalized during the Infrastructure Implementation Meeting held at each pilot facility. Apart from that, users were also introduced with ADKAR (Awareness, Desire, Knowledge, Ability, Reinforcement) concept during the Change Management Program at facility.
28 PROGRAM FARMASI / PHARMACY PROGRAMME
LAPORAN TAHUNANANNUAL REPORT2012
24 | L a p o r a n T a h u n a n 2 0 1 2
In 2012, PSD has emphasized on the importance of the development of the Pharmacy Hospital
Information System (PHIS) and the Clinical Pharmacy Information System (CPS). This project focused
on the development of 12 modules in the system throughout the year 2012. Achievements of system
development until 31 December 2012 are shown in Table 12.
A total of 14 activities such as workshops, reviews, visits and meetings were held to validate and verify
the user requirements before finalizing the User Requirement Specification (URS) document and
System Design Documentation (SDD).
Besides system development, implementation readiness and preparation activities were conducted
extensively at pilot facilities as shown in Table 13. This is to ensure that all facilities have adequate
infrastructure ensure and user-readiness towards implementing the system in their facilities.
Allocation of hardware was finalized during the Infrastructure Implementation Meeting held at each
pilot facility. Apart from that, users were also introduced with ADKAR (Awareness, Desire, Knowledge,
Ability, Reinforcement) concept during the Change Management Program at facility.
Jadual 12: Aktiviti Pembangunan Sistem
Table 12: System Development Activities
Bil. No.
Aktiviti
Activities
Pencapaian Achievements
1
Mesyuarat KICK OFF untuk memulakan projek Kick OFF Meeting to start the project
Project Initiation Document (PID) v1.2 dan project plan v.3.2 disahkan oleh Project Implementation Technical Committee (PITC). Project Initiation Document (PID) v1.2 and project plan v.3.2 were endorsed by Project Implementation Technical Committee (PITC)
2
Bengkel Penyediaan dan Pengesahan keperluan pengguna (4 sesi) Workshop on Preparation and Verification on User Requirements (4 session)
User Requirement Specification (URS) v1.3 dimuktamadkan pada 15 Februari 2012 User Requirement Specification (URS) v1.3 was finalized on 15 Feb 2012
3
Bengkel Semakan Rekabentuk Sistem (2 sesi) Workshop on System Design Review (2 session)
System Design Documentation (SDD) v1.2 dimuktamadkan pada 12 Apr 2012 System Design Documentation (SDD) v1.2 was finalized on 12 Apr 2012
4
Bengkel/Mesyuarat Pembangunan Data (8 sesi) Workshop/ meetings on Data Preparation and Development (8 session)
Spesifikasi data ubat dan bukan ubat telah dimuktamadkan pada Julai 2012. Proses validasi data dijalankan secara berterusan sehingga pembangunan sistem selesai. Drug and non drug data specifications was finalized on July 2012. Data validation process will be carried out continously until system development is completed.
29PROGRAM FARMASI / PHARMACY PROGRAMME
LAPORAN TAHUNANANNUAL REPORT 2012
25 | L a p o r a n T a h u n a n 2 0 1 2
Jadual 13: Aktiviti Persediaan Pelaksanaan di Fasiliti Perintis
Table 13: Implementation Readiness/Preparation Activities at Pilot Facilities
Bil. No.
Aktiviti Activities
Pencapaian Achievements
1
Majlis Dialog dan Kunjungan Hormat di Fasiliti Perintis Dialogue session and Courtesy visit at Pilot Facilities
i) Kunjungan hormat di PKD Kinta : 18 April 2012 i) Courtesy visit at PKD Kinta : 18 April 2012 ii) Majlis Dialog di Hospital Pakar Sultanah Fatimah, Muar : 11 Jun 2012 ii) Dialogue session at Hospital Pakar Sultanah Fatimah, Muar : 11 June 2012 iii) Kunjungan hormat di JKN Perak : 30 November 2012 iii) Courtesy visit at JKN Perak : 30 November 2012 iv) Kunjungan hormat di JKN Kelantan : 3 Disember 2012 iv) Courtesy visit at JKN Kelantan : 3 December 2012 v) Kunjungan hormat di JKN Sarawak : 19 Disember 2012 v) Courtesy visit at JKN Sarawak : 19 December 2012 vi) Majlis Dialog di Hospital Miri, Sarawak : 20 Disember 2012 vi) Dialogue session at Hospital Miri, Sarawak : 20 December 2012
2
Program Pengurusan Perubahan di Ibu Pejabat dan fasiliti pilot Change Management Program at Headquarters and Pilot Facilities
i) Mesyuarat penyediaan dan semakan kandungan Program Pengurusan Perubahan - 4 Mei, 7 Mei, 16 Mei, 21-22 Mei, 28 Jun dan 4 Julai 2012 i) Meeting for preparation and content review for Change Management Program - 4 May, 7 May, 16 May, 21-22 May, 28 June dan 4 July 2012 ii) Bengkel Pengurusan Perubahan di HPSF, Muar : 7 Julai 2012 ii) Change Management Workshop at HPSF, Muar : 7 July 2012 iii) Bengkel Pengurusan Perubahan di PKD Kinta : 13 September 2012 iii) Change Management Workshop at PKD Kinta : 13 September 2012 iv) Bengkel Pengurusan Perubahan di Hospital Seri Manjung : 5 Disember 2012 iv) Change Management Workshop at Hospital Seri Manjung : 5 December 2012
25 | L a p o r a n T a h u n a n 2 0 1 2
Jadual 13: Aktiviti Persediaan Pelaksanaan di Fasiliti Perintis
Table 13: Implementation Readiness/Preparation Activities at Pilot Facilities
Bil. No.
Aktiviti Activities
Pencapaian Achievements
1
Majlis Dialog dan Kunjungan Hormat di Fasiliti Perintis Dialogue session and Courtesy visit at Pilot Facilities
i) Kunjungan hormat di PKD Kinta : 18 April 2012 i) Courtesy visit at PKD Kinta : 18 April 2012 ii) Majlis Dialog di Hospital Pakar Sultanah Fatimah, Muar : 11 Jun 2012 ii) Dialogue session at Hospital Pakar Sultanah Fatimah, Muar : 11 June 2012 iii) Kunjungan hormat di JKN Perak : 30 November 2012 iii) Courtesy visit at JKN Perak : 30 November 2012 iv) Kunjungan hormat di JKN Kelantan : 3 Disember 2012 iv) Courtesy visit at JKN Kelantan : 3 December 2012 v) Kunjungan hormat di JKN Sarawak : 19 Disember 2012 v) Courtesy visit at JKN Sarawak : 19 December 2012 vi) Majlis Dialog di Hospital Miri, Sarawak : 20 Disember 2012 vi) Dialogue session at Hospital Miri, Sarawak : 20 December 2012
2
Program Pengurusan Perubahan di Ibu Pejabat dan fasiliti pilot Change Management Program at Headquarters and Pilot Facilities
i) Mesyuarat penyediaan dan semakan kandungan Program Pengurusan Perubahan - 4 Mei, 7 Mei, 16 Mei, 21-22 Mei, 28 Jun dan 4 Julai 2012 i) Meeting for preparation and content review for Change Management Program - 4 May, 7 May, 16 May, 21-22 May, 28 June dan 4 July 2012 ii) Bengkel Pengurusan Perubahan di HPSF, Muar : 7 Julai 2012 ii) Change Management Workshop at HPSF, Muar : 7 July 2012 iii) Bengkel Pengurusan Perubahan di PKD Kinta : 13 September 2012 iii) Change Management Workshop at PKD Kinta : 13 September 2012 iv) Bengkel Pengurusan Perubahan di Hospital Seri Manjung : 5 Disember 2012 iv) Change Management Workshop at Hospital Seri Manjung : 5 December 2012
26 | L a p o r a n T a h u n a n 2 0 1 2
3
Persediaan Pelaksanaan Infrastruktur di Fasiliti Pilot Infrastructure Implementation Readiness at Pilot Facilities
i) Mesyuarat Pelaksanaan Infrastruktur di HPSF, Muar : 3 September 2012
i) Infrastructure Implementation Meeting at HPSF, Muar : 3 September 2012 ii) Mesyuarat Pelaksanaan Infrastruktur di PKD Kinta : 12 September 2012
ii) Infrastructure Implementation Meeting at PKD Kinta : 12 September 2012 iii) Mesyuarat Pelaksanaan Infrastruktur di Hosp. Seri Manjung: 6 Disember 2012 iii) Infrastruture Implementation Meeting at Hosp. Seri Manjung: 6 December 2012 iv) Mesyuarat Pelaksanaan Infrastruktur di Hosp. Tanah Merah: 23 Disember 2013 iv) Infrastructure Implementation Meeting at Hosp. Tanah Merah: 23 December 2013
Sistem Pengurusan dan Kawalan Substan (SPIKES)
Integrated Substance Control Management System (SPIKES)
SPIKES (www.myspikes.gov.my) ialah satu sistem pengurusan dan kawalan substan yang
dibangunkan hasil dari sub-inisiatif Pengekangan Bekalan Dadah (Drug Supply Suppression) di
bawah inisiatif mengurangkan kadar jenayah jalanan di bawah Makmal Jenayah NKRA. SPIKES
mengintegrasikan kawalan substan (bahan-bahan narkotik, bahan-bahan psikotropik dan kimia
prekursor) dengan kolaborasi perkongsian maklumat substan dengan agensi-agensi kerajaan yang
menguatkuasakan kawalan dadah negara seperti Agensi Anti Dadah Kebangsaan (AADK), Polis
DiRaja Malaysia (PDRM), Kastam DiRaja Malaysia (KDRM), Jabatan Kimia Malaysia (JKM) dan
Bahagian Perkhidmatan Farmasi, Kementerian Kesihatan Malaysia (BPF KKM). Sebagai pihak
berkuasa berwibawa (competent authority) kawalan substan di negara ini, BPF KKM telah dilantik
sebagai agensi peneraju bagi menjalankan inisiatif SPIKES ini.
Sistem Pengurusan Integrasi Kawalan Efektif Substan (SPIKES) telah dilancarkan di Dewan
Anggerik, Biro Pengawalan Farmaseutikal Kebangsaan KKM pada 23 Februari 2012.
SPIKES is a system that is used in the management and control of substances. It was developed as
an outcome of the Drug Supply Suppression sub-initiative of the National Key Results Area (NKRA)
Crime Lab under the Government Transformation Programme (GTP). SPIKES integrates control of
substances (narcotics, psychotropic substances and precursor chemicals) and facilitates substance
30 PROGRAM FARMASI / PHARMACY PROGRAMME
LAPORAN TAHUNANANNUAL REPORT2012
Sistem Pengurusan dan Kawalan Substan (SPIKES)Integrated Substance Control Management System (SPIKES)
SPIKES (www.myspikes.gov.my) ialah satu sistem pengurusan dan kawalan substan yang dibangunkan hasil dari sub-inisiatif Pengekangan Bekalan Dadah (Drug Supply Suppression) di bawah inisiatif mengurangkan kadar jenayah jalanan di bawah Makmal Jenayah NKRA. SPIKES mengintegrasikan kawalan substan (bahan-bahan narkotik, bahan-bahan psikotropik dan kimia prekursor) dengan kolaborasi perkongsian maklumat substan dengan agensi-agensi kerajaan yang menguatkuasakan kawalan dadah negara seperti Agensi Anti Dadah Kebangsaan (AADK), Polis DiRaja Malaysia (PDRM), Kastam DiRaja Malaysia (KDRM), Jabatan Kimia Malaysia (JKM) dan Bahagian Perkhidmatan Farmasi, Kementerian Kesihatan Malaysia (BPF KKM). Sebagai pihak berkuasa berwibawa (competent authority) kawalan substan di negara ini, BPF KKM telah dilantik sebagai agensi peneraju bagi menjalankan inisiatif SPIKES ini.
Sistem Pengurusan Integrasi Kawalan Efektif Substan (SPIKES) telah dilancarkan di Dewan Anggerik, Biro Pengawalan Farmaseutikal Kebangsaan KKM pada 23 Februari 2012.
SPIKES is a system that is used in the management and control of substances. It was developed as an outcome of the Drug Supply Suppression sub-initiative of the National Key Results Area (NKRA) Crime Lab under the Government Transformation Programme (GTP). SPIKES integrates control of substances (narcotics, psychotropic substances and precursor chemicals) and facilitates substance information sharing among other relevant enforcement agencies such as the National Anti Drug Agency (NADA), Narcotics Crime Investigation Department, Royal Malaysian Police (RMP), Preventive Division (Narcotics), Royal Malaysian Customs (RMC), Narcotics Section, Forensics Divison, Chemistry Department of Malaysia (CDM) and Pharmacy Enforcement, Pharmaceutical Services Division, Ministry of Health (MOH). PSD MOH as the nation’s competent authority for the control of substances has been appointed as the lead agency to conduct this collaboration.
SPIKES had been officially launched on 23rd February 2012 at the Anggerik Hall, National Pharmaceutical Control Bureau of Health.
31PROGRAM FARMASI / PHARMACY PROGRAMME
LAPORAN TAHUNANANNUAL REPORT 2012
27 | L a p o r a n T a h u n a n 2 0 1 2
information sharing among other relevant enforcement agencies such as the National Anti Drug
Agency (NADA), Narcotics Crime Investigation Department, Royal Malaysian Police (RMP),
Preventive Division (Narcotics), Royal Malaysian Customs (RMC), Narcotics Section, Forensics
Divison, Chemistry Department of Malaysia (CDM) and Pharmacy Enforcement, Pharmaceutical
Services Division, Ministry of Health (MOH). PSD MOH as the nation’s competent authority for the
control of substances has been appointed as the lead agency to conduct this collaboration.
SPIKES had been officially launched on 23rd
October 2012 at the Anggerik Hall, National
Pharmaceutical Control Bureau of Health.
Rajah 11 : Upacara Majlis Pelancaran SPIKES
Figure 11 : Official Launching of SPIKES
28 | L a p o r a n T a h u n a n 2 0 1 2
Rajah 12 : Agensi-agensi lain terlibat dalam SPIKES
Figure 12 : Stakeholders in SPIKES
9. Tadbir Urus Baik Ubat
Good Governance for Medicines (GGM)
Dua garis panduan Good Governance of Medicines (GGM) ini telah dikemaskini dan diterbitkan pada
November 2012, iaitu Garis panduan Pemberian dan Penerimaan Hadiah untuk Anggota Farmasi,
KKM dan Garis panduan untuk Anggota Farmasi KKM Berurusan dengan Wakil Syarikat
Farmaseutikal dan Pembekal.
Unit GGM telah menerima penajaan daripada WHO Representative Office for Brunei Darussalam,
Malaysia dan Singapore sebanyak RM64,554 bagi tujuan menerbitkan garis panduan GGM dan
membangunkan modul latihan Training of Trainers (TOT) Good Governance for Medicines (GGM).
Beberapa bengkel penyediaan modul latihan TOT GGM telah diadakan seperti berikut:
• 8-9hb Mac 2012
• 2-3 April 2012
• 4-5 Jun 2012
• 5-7 November 2012 (tajaan WHO)
• 4-5 Disember 2012 (tajaan WHO)
32 PROGRAM FARMASI / PHARMACY PROGRAMME
LAPORAN TAHUNANANNUAL REPORT2012
9. Tadbir Urus Baik Ubat Good Governance for Medicines (GGM)
Dua garis panduan Good Governance of Medicines (GGM) ini telah dikemaskini dan diterbitkan pada November 2012, iaitu Garis panduan Pemberian dan Penerimaan Hadiah untuk Anggota Farmasi, KKM dan Garis panduan untuk Anggota Farmasi KKM Berurusan dengan Wakil Syarikat Farmaseutikal dan Pembekal.
Unit GGM telah menerima penajaan daripada WHO Representative Office for Brunei Darussalam, Malaysia dan Singapore sebanyak RM64,554.00 bagi tujuan menerbitkan garis panduan GGM dan membangunkan modul latihan Training of Trainers (TOT) Good Governance for Medicines (GGM).
Beberapa bengkel penyediaan modul latihan TOT GGM telah diadakan seperti berikut:
• 8-9 Mac 2012• 2-3 April 2012• 4-5 Jun 2012• 5-7 November 2012 (tajaan WHO)• 4-5 Disember 2012 (tajaan WHO)
Two GGM guidelines were revised and published in November 2012. They are the Guidelines on Giving and Receiving Gifts for Civil Servants under the Pharmacy Program, Ministry of Health Malaysia and Guidelines for Pharmacy Personnel in Dealing with Pharmaceutical Company Representatives and Suppliers.
The GGM unit received co-sponsorship from the WHO Representative Office for Brunei Darussalam, Malaysia and Singapore for the GGM TOT workshops and the publication of the GGM guidelines. The fund awarded was RM64, 554.00. Several workshops to develop the GGM TOT module were conducted on these respective dates:
• 8th – 9th March 2012• 2nd – 3rd April 2012• 4th -5th June 2012• 5th – 7th November 2012 (sponsored by WHO)• 4th – 5th December 2012 (sponsored by WHO)
33PROGRAM FARMASI / PHARMACY PROGRAMME
LAPORAN TAHUNANANNUAL REPORT 2012
29 | L a p o r a n T a h u n a n 2 0 1 2
Two GGM guidelines were revised and published in November 2012. They are the Guidelines on
Giving and Receiving Gifts for Civil Servants under the Pharmacy Program, Ministry of Health
Malaysia and Guidelines for Pharmacy Personnel in Dealing with Pharmaceutical Company
Representatives and Suppliers.
The GGM unit received co-sponsorship from the WHO Representative Office for Brunei Darussalam,
Malaysia and Singapore for the GGM TOT workshops and the publication of the GGM guidelines. The
fund awarded was RM64, 554.00. Several workshops to develop the GGM TOT module were
conducted on these respective dates:
• 8th – 9
th March 2012
• 2nd
– 3rd
April 2012
• 4th -5
th June 2012
• 5th – 7
th November 2012 (sponsored by WHO)
• 4th – 5
th December 2012 (sponsored by WHO)
Jadual 14: Pencapaian GGM Tahun 2012
Table 14: Achievements of GGM in 2012
Bil.
No.
Aktiviti
Activities
Output
Outputs
Pencapaian
Achievements
1.
Penyediaan Modul Latihan Training of Trainers
(TOT) GGM
Development of GGM Training of Trainers (TOT)
Module
Modul TOT GGM
The GGM TOT Module
Akan dimurnikan dan
dilancarkan pada tahun
2013.
To be endorsed and
implemented in 2013.
2. Penyemakan semula dua garis panduan GGM.
Revision of two (2) GGM guidelines
Penerbitan dua garis panduan
GGM edisi kedua.
Publication of the 2nd
edition of
two GGM guidelines.
Garis panduan GGM
diedarkan dan digunapakai
di seluruh negara.
Distribution and
implementation of the new
GGM guidelines nationwide
29 | L a p o r a n T a h u n a n 2 0 1 2
Two GGM guidelines were revised and published in November 2012. They are the Guidelines on
Giving and Receiving Gifts for Civil Servants under the Pharmacy Program, Ministry of Health
Malaysia and Guidelines for Pharmacy Personnel in Dealing with Pharmaceutical Company
Representatives and Suppliers.
The GGM unit received co-sponsorship from the WHO Representative Office for Brunei Darussalam,
Malaysia and Singapore for the GGM TOT workshops and the publication of the GGM guidelines. The
fund awarded was RM64, 554.00. Several workshops to develop the GGM TOT module were
conducted on these respective dates:
• 8th – 9
th March 2012
• 2nd
– 3rd
April 2012
• 4th -5
th June 2012
• 5th – 7
th November 2012 (sponsored by WHO)
• 4th – 5
th December 2012 (sponsored by WHO)
Jadual 14: Pencapaian GGM Tahun 2012
Table 14: Achievements of GGM in 2012
Bil.
No.
Aktiviti
Activities
Output
Outputs
Pencapaian
Achievements
1.
Penyediaan Modul Latihan Training of Trainers
(TOT) GGM
Development of GGM Training of Trainers (TOT)
Module
Modul TOT GGM
The GGM TOT Module
Akan dimurnikan dan
dilancarkan pada tahun
2013.
To be endorsed and
implemented in 2013.
2. Penyemakan semula dua garis panduan GGM.
Revision of two (2) GGM guidelines
Penerbitan dua garis panduan
GGM edisi kedua.
Publication of the 2nd
edition of
two GGM guidelines.
Garis panduan GGM
diedarkan dan digunapakai
di seluruh negara.
Distribution and
implementation of the new
GGM guidelines nationwide
BIRO PENGAWALAN FARMASEUTIKAL KEBANGSAAN (BPFK)
NATIONAL PHARMACEUTICAL CONTROL BUREAU (NPCB)
36 PROGRAM FARMASI / PHARMACY PROGRAMME
LAPORAN TAHUNANANNUAL REPORT2012
BIRO PENGAWALAN FARMASEUTIKAL KEBANGSAAN (BPFK)NATIONAL PHARMACEUTICAL CONTROL BUREAU (NPCB)
1. Pensijilan 5S 5S Certification
Amalan 5S yang berasal dari negara Jepun kini telah menjadi praktis di Malaysia. Amalan ini memberi penekanan kepada penjagaan persekitaran tempat kerja yang sistematik bagi meningkatkan produktiviti. Kerajaan Malaysia menyokong sepenuhnya amalan ini dalam usaha untuk meningkatkan kecekapan perkhidmatan awam.
Selaras dengan itu, Biro Pengawalan Farmaseutikal Kebangsaan (BPFK) telah melancarkan kempen 5S pada bulan Julai 2010. BPFK telah melalui beberapa siri audit dalaman serta audit luaran dan berjaya mendapat markah purata sebanyak 96.23% pada audit terakhir. Dengan itu, BPFK dianugerahkan pensijlan 5S dari Unit Pemodenan Tadbiran & Perancangan Pengurusan Malaysia (MAMPU) pada 17 Disember 2012 sehingga ke pensijilan semula selepas dua tahun dari tarikh tersebut.
The 5S practice, which originated from Japan, is now being adapted in the country. This practice emphasizes on maintaining a systematic work environment in order to increase productivity. The Malaysian government fully supports this practice in the effort to improve efficiency of the public service.
In line with this, the National Pharmaceutical Control Bureau (NPCB) launched the 5S campaign back in July 2010. The NPCB went through a series of internal and external audits and scored an average of 96.23% during the final audit. NPCB was then awarded the 5S certification from the Malaysia Administrative Modernisation & Management Planning Unit (MAMPU) on 17 December 2012. The certificate has been issued with effect from 17 December 2012 to 17 December 2014.
2. Mesyuarat Teknikal Pertama Pembangunan dan Penyelarasan Standard Farmaseutikal dan Vaksin bagi Negara-negara Pertubuhan Islam (OIC)
1st Technical Meeting on Development and Harmonisation of Standards on Pharmaceuticals and Vaccines (DHSPV) among OIC Member States
Mesyuarat Teknikal Pertama Pembangunan dan Penyelarasan Standard Farmaseutikal dan Vaksin bagi Negara-negara Pertubuhan Islam (OIC-DHSPV) telah diadakan pada 1 – 2 Oktober 2012 di Pusat Perdagangan Dunia Putra, Kuala Lumpur. Penganjuran mesyuarat ini adalah hasil usaha sama di antara Kementerian Sains, Teknologi dan Inovasi (MOSTI) dan Kementerian Kesihatan Malaysia (KKM) dengan kerjasama daripada Sektretariat OIC.
Mesyuarat Teknikal ini telah dihadiri oleh wakil negara-negara OIC seperti Brunei Darussalam, Gambia, Indonesia, Malaysia and Saudi Arabia, di samping wakil-wakil dari badan-badan antarabangsa iaitu World Health Organization (WHO), Statistical, Economic and Social Research and Training Centre for Islamic Countries (SESRIC) dan Islamic Development Bank (IDB).
Mesyuarat ini telah diadakan sebagai salah satu inisiatif negara-negara anggota OIC ke arah pengeluaran farmaseutikal dan vaksin sendiri bagi memastikan bekalan farmaseutikal dan vaksin di negara-negara anggota OIC adalah berkualiti tinggi, selamat dan berkesan dengan harga yang berpatutan.
37PROGRAM FARMASI / PHARMACY PROGRAMME
LAPORAN TAHUNANANNUAL REPORT 2012
Hasil daripada mesyuarat tersebut, beberapa perkara telah dipersetujui, antaranya termasuk Terms of Reference (ToR) and Struktur Jawatankuasa Teknikal OIC-DHSPV. Mesyuarat Teknikal ke-2 dicadang untuk diadakan pada tahun 2013.
The 1st Techinical Meeting on Development and Harmonisation of Standards on Pharmaceuticals and Vaccines (DHSPV) among OIC Member States was held at Putra World Trade Centre, Kuala Lumpur on 1-2 October 2012. The organization of this meeting is a joint effort between the Ministry of Science, Technology and Innovation (MOSTI) and Ministry of Health Malaysia (MOH) in collaboration with the OIC General Secretariat.
The meeting was attended by representatives from the OIC Member States i.e. Brunei Darussalam, Gambia, Indonesia, Malaysia and Saudi Arabia, as well as international bodies i.e. World Health Organization (WHO), Statistical, Economic and Social Research and Training Centre for Islamic Countries (SESRIC) and Islamic Development Bank (IDB).
The meeting was held as an initiative of the OIC Member States towards production and self-reliance of pharmaceuticals and vaccines to ensure reliable supply of good quality, safe, effective and affordable medicines and vaccines.
The meeting deliberated on the Terms of Reference (ToR) and the structure of the OIC-DHSPV Technical Committee. The 2nd Technical Meeting will be conducted in 2013.
32 | L a p o r a n T a h u n a n 2 0 1 2
The meeting deliberated on the Terms of Reference (ToR) and the structure of the OIC-DHSPV
Technical Committee. The 2nd
Technical Meeting will be conducted in 2013.
Rajah 13 : Mesyuarat Teknikal Pertama Pembangunan dan Penyelarasan Standard Farmaseutikal
dan Vaksin bagi Negara-negara Pertubuhan Islam
Figure 13 : 1st Technical Meeting on Development and Harmonisation of Standards on
Pharmaceuticals and Vaccines (DHSPV) among OIC Member States
3. Mesyuarat Teknikal Dua Hala bersama Badan Regulatori Luar
Bilateral Meeting with Other Regulatory Agencies
(a) BPFK dan Badan Pengawas Obat dan Makanan (BPOM), Republik
Indonesia
(a) NPCB and National Agency of Drug and Food Control (NA-DFC), Republic of Indonesia
Mesyuarat Teknikal Dua Hala antara BPFK dan BPOM telah diadakan pada 11 Jun 2012 dalam
usaha mempertingkatkan hubungan dan kerjasama dalam bidang regulatori farmaseutikal di
antara Malaysia dan Indonesia.
38 PROGRAM FARMASI / PHARMACY PROGRAMME
LAPORAN TAHUNANANNUAL REPORT2012
3. Mesyuarat Teknikal Dua Hala bersama Badan Regulatori Luar Bilateral Meeting with Other Regulatory Agencies
(a) BPFK dan Badan Pengawas Obat dan Makanan (BPOM), Republik Indonesia
(a) NPCB and National Agency of Drug and Food Control (NA-DFC), Republic of Indonesia
Mesyuarat Teknikal Dua Hala antara BPFK dan BPOM telah diadakan pada 11 Jun 2012 dalam usaha mempertingkatkan hubungan dan kerjasama dalam bidang regulatori farmaseutikal di antara Malaysia dan Indonesia.
Mesyuarat ini telah berlangsung di Boulevard Hotel, Mid Valley, Kuala Lumpur dan melibatkan seramai 21 orang pegawai (dihadiri oleh lima orang pegawai regulatori dari BPOM, 14 orang pegawai dari BPFK serta dua orang wakil dari Bahagian Dasar & Hubungan Antarabangsa, Kementerian Kesihatan Malaysia). Mesyuarat turut dihadiri oleh seorang wakil dari Kedutaan Republik Indonesia sebagai pemerhati.
The Bilateral Meeting between NPCB and NA-DFC was conducted on 11 June 2012 as an initiative to improve the working relationship between Malaysia and Indonesia in the pharmaceutical regulatory field.
The meeting was held at Boulevard Hotel, Mid Valley, Kuala Lumpur and was attended by 21 officers (5 officers from NA-DFC, 14 officers from NPCB and 2 representatives from the Policy and International Relations Division, Ministry of Health, Malaysia). A representative from the Embassy of The Republic of Indonesian was also present as an observer.
33 | L a p o r a n T a h u n a n 2 0 1 2
Mesyuarat ini telah berlangsung di Boulevard Hotel, Mid Valley, Kuala Lumpur dan melibatkan
seramai 21 orang pegawai (dihadiri oleh lima orang pegawai regulatori dari BPOM, 14 orang
pegawai dari BPFK serta dua orang wakil dari Bahagian Dasar & Hubungan Antarabangsa,
Kementerian Kesihatan Malaysia). Mesyuarat turut dihadiri oleh seorang wakil dari Kedutaan
Republik Indonesia sebagai pemerhati.
The Bilateral Meeting between NPCB and NA-DFC was conducted on 11 June 2012 as an
initiative to improve the working relationship between Malaysia and Indonesia in the
pharmaceutical regulatory field.
The meeting was held at Boulevard Hotel, Mid Valley, Kuala Lumpur and was attended by 21
officers (5 officers from NA-DFC, 14 officers from NPCB and 2 representatives from the Policy
and International Relations Division, Ministry of Health, Malaysia). A representative from the
Embassy of The Republic of Indonesian was also present as an observer.
Rajah 14: Mesyuarat Teknikal Dua Hala BPFK dan BPOM, Republik Indonesia
Figure 14 : Technical Bilateral Meeting between NPCB & NA-DFC
39PROGRAM FARMASI / PHARMACY PROGRAMME
LAPORAN TAHUNANANNUAL REPORT 2012
(b) BPFK dan Food and Drug Administration of Thailand (Thai FDA)
(b) NPCB and Food and Drug Administration of Thailand (Thai FDA)
Mesyuarat Teknikal Dua Hala di antara BPFK dan Thai FDA telah diadakan pada 2 Julai 2012 di Siam City Hotel, Bangkok, Thailand. Mesyuarat telah dihadiri oleh YBhg. Dato’ Eisah A. Rahman, Pengarah Kanan Perkhidmatan Farmasi, Kementerian Kesihatan Malaysia dan 4 orang pegawai BPFK serta 9 orang pegawai dari Thai FDA.
Mesyuarat tersebut telah membincangkan bidang kerjasama yang boleh dijalinkan di antara kedua-dua negara termasuk perkongsian maklumat berkenaan kawalan regulatori produk farmaseutikal dan program pemantauan produk di pasaran, mengadakan jaringan dan kerjasama dalam menangani masalah kekurangan ubat yang sangat diperlukan serta ubat ‘orphan’ terutama semasa krisis, kecemasan atau malapetaka serta pertukaran pengalaman berkaitan permohonan dan penghantaran maklumat atas talian.
The Bilateral Meeting between NPCB and Thai FDA was held at Siam City Hotel, Bangkok, Thailand on 2 July 2012. The meeting was attended by YBhg. Dato’ Eisah A. Rahman, Senior Director of Pharmaceutical Services, Ministry of Health Malaysia along with 4 NPCB officers and 9 officers from Thai FDA.
The meeting discussed issues in the field of cooperation between the two countries including sharing of information regarding regulatory control of pharmaceutical products and market surveillance of products, network formation and cooperation in matters pertaining to shortage of medicine supply especially orphan drugs during crisis, emergencies and natural disasters, and exchange of experiences related to online application and delivery of information.
(c) BPFK dan Health Sciences Authority (HSA), Singapura
(c) NPCB and Health Sciences Authority (HSA), Singapore
Mesyuarat Teknikal Dua Hala antara BPFK dan HSA telah diadakan dengan jayanya pada 9 April 2012 di Gardens Hotel & Residences, Kuala Lumpur. Mesyuarat ini telah dipengerusikan bersama oleh YBhg. Dato’ Eisah A. Rahman, Pengarah Kanan Perkhidmatan Farmasi, Kementerian Kesihatan Malaysia dan Prof. John Lim, Ketua Pegawai Eksekutif, Health Sciences Authority, Singapura. Mesyuarat ini telah dihadiri oleh 31 orang pegawai dari kedua-dua buah negara (21 delegasi Malaysia dan 10 delegasi dari HSA, Singapura). Antara perkara yang telah dibincangkan adalah pemeriksaan bersama dari aspek Amalan Perkilangan Baik, pemeriksaan tapak BA/BE, penilaian bersama bagi “dossiers”, isu penguatkuasaan serta latihan antara agensi.
Hasil daripada mesyuarat ini, satu program kerjasama dalam bidang regulatori farmaseutikal di antara BPFK dengan HSA telah dibangunkan dan dipersetujui oleh kedua-dua pihak. Mesyuarat juga bersetuju agar mesyuarat ini diadakan setiap tahun dan HSA akan menjadi tuan rumah bagi tahun 2013.
40 PROGRAM FARMASI / PHARMACY PROGRAMME
LAPORAN TAHUNANANNUAL REPORT2012
The Bilateral Meeting between NPCB and HSA was held successfully on 9 April 2012 at the Gardens Hotel & Residences, Kuala Lumpur. This meeting was chaired by YBhg. Dato’ Eisah A. Rahman, Senior Director of Pharmaceutical Services, Ministry of Health, Malaysia and Prof. John Lim, Chief Executive Officer of the Health Sciences Authority, Singapore. The meeting was attended by 31 officers from both countries (21 delegates from Malaysia and 10 delegates from HSA, Singapore). Among the issues discussed were Good Manufacturing Practice (GMP) joint inspection, inspection of BA/BE sites, joint evaluation of dossiers, enforcement issues and training for both agencies.
At the end of the meeting, a programme of cooperation in the field of pharmaceutical regulatory between NPCB and HSA was developed and agreed upon by both parties. Both parties also agreed that the bilateral meeting is to be conducted every year and HSA will be the host for the year 2013.
35 | L a p o r a n T a h u n a n 2 0 1 2
Hasil daripada mesyuarat ini, satu program kerjasama dalam bidang regulatori farmaseutikal di antara
BPFK dengan HSA telah dibangunkan dan dipersetujui oleh kedua-dua pihak. Mesyuarat juga
bersetuju agar mesyuarat ini diadakan setiap tahun dan HSA akan menjadi tuan rumah bagi tahun
2013.
The Bilateral Meeting between NPCB and HSA was held successfully on 9 April 2012 at the Gardens
Hotel & Residences, Kuala Lumpur. This meeting was chaired by YBhg. Dato’ Eisah A. Rahman,
Senior Director of Pharmaceutical Services, Ministry of Health, Malaysia and Prof. John Lim, Chief
Executive Officer of the Health Sciences Authority, Singapore. The meeting was attended by 31
officers from both countries (21 delegates from Malaysia and 10 delegates from HSA, Singapore).
Among the issues discussed were Good Manufacturing Practice (GMP) joint inspection, inspection of
BA/BE sites, joint evaluation of dossiers, enforcement issues and training for both agencies.
At the end of the meeting, a programme of cooperation in the field of pharmaceutical regulatory
between NPCB and HSA was developed and agreed upon by both parties. Both parties also agreed
that the bilateral meeting is to be conducted every year and HSA will be the host for the year 2013.
Rajah 15 : Mesyuarat Teknikal Dua Hala BPFK dan HSA, Singapura
Figure 15 : Bilateral Meeting between NPCB & HSA
.
41PROGRAM FARMASI / PHARMACY PROGRAMME
LAPORAN TAHUNANANNUAL REPORT 2012
4. Memorandum Persefahaman (MoU) antara Kementerian Kesihatan Malaysia dan Health Sciences Authority, Singapura 4. Memorandum of Understanding (MoU) between Ministry of Health, Malaysia and Health Sciences Authority (HSA), Singapore
Memorandum Persefahaman (MoU) antara Kementerian Kesihatan Malaysia (KKM) dan Health Sciences Authority (HSA), Singapura telah berjaya ditandatangani pada 28 Mac 2012 di Singapura. Majlis ini telah disaksikan oleh Menteri Kesihatan dari kedua-dua negara. Ia merupakan salah satu peristiwa penting bagi Biro Pengawalan Farmaseutikal Kebangsaan secara khususnya dan Bahagian Perkhidmatan Farmasi secara amnya kerana ia merupakan MoU pertama yang berjaya ditandatangani oleh Malaysia dalam bidang regulatori farmaseutikal.
Antara bidang kerjasama yang telah dipersetujui adalah kerjasama dalam bidang regulatori farmaseutikal, perkongsian maklumat berkaitan aktiviti penguatkuasaan, surveilans, farmakovigilans, pengujian sampel, pemeriksaan Amalan Perkilangan Baik dan kajian klinikal serta kolaborasi dalam semua bidang yang mempunyai impak ke atas kesihatan awam yang berkaitan dengan produk farmaseutikal.
A Memorandum of Understanding (MoU) between the Ministry of Health, Malaysia and Health Sciences Authority (HSA), Singapore was successfully signed on 28 March 2012 in Singapore. The memorable event was witnessed by the Minister of Health of both countries. This was a very significant event particularly for the National Pharmaceutical Control Bureau and the Pharmaceutical Services Division as it is the first MoU signed by Malaysia in the field of pharmaceutical regulatory.
Among the field of cooperation which has been agreed upon is the pharmaceutical regulatory field, information sharing in regards to enforcement activities, surveillance, pharmacovigilance, sample testing, Good Manufacturing Practice inspections and clinical studies along with collaboration in all fields relating to pharmaceutical products which has an impact on the health of the public.
HALATUJU
WAY FORWARD
44 PROGRAM FARMASI / PHARMACY PROGRAMME
LAPORAN TAHUNANANNUAL REPORT2012
AMALAN DAN PERKEMBANGAN FARMASI
Aktiviti-aktiviti yang dijalankan oleh Amalan dan Perkembangan Farmasi tertumpu kepada memberi perkhidmatan penjagaan farmasi yang terbaik bersesuaian dengan keperluan pada masa kini. Bagi menyediakan sistem penjagaan kesihatan yang seragam dan berkualiti, garis panduan dan modul latihan akan dikemaskini. Di samping itu, perkhidmatan Home Medication Review akan diperluaskan supaya kesinambungan penjagaan dari fasiliti kesihatan ke rumah pesakit dapat diteruskan.
Strategi yang akan dijalankan bagi memperkukuhkan penggunaan ubat secara berkualiti ialah melalui perluasan aktiviti Duta Kenali Ubat Anda ke peringkat negeri. Aktiviti-aktiviti ini memberi penghakupayaan masyarakat terhadap penggunaan ubat secara lebih bertanggungjawab dan dengan itu akan dapat membantu meningkatkan penggunaan ubat secara berkesan dan selamat.
Bahagian ini juga menekankan kewujudan ekosistem yang menyokong pertumbuhan penyelidikan klinikal melalui meningkatkan daya saing antara penyelidik serta penyebaran dan penggunaan bukti penyelidikan untuk meningkatkan mutu perkhidmatan.
Berdasarkan pelan strategik Dasar Ubat Nasional, bahagian ini akan menumpukan aktiviti-aktiviti ke arah memastikan ketersediaan ubat-ubat yang selamat, berkesan, berkualiti dan kos efektif secara berterusan serta meningkatkan akses kepada maklumat harga ubat–ubatan yang mampu diperolehi oleh rakyat. Tahun 2013 akan melibatkan perbincangan dengan pihak yang berkepentingan untuk mencapai objektif ini.
Bagi memastikan ahli farmasi yang kompeten dan memenuhi keperluan di
PHARMACY PRACTICE AND DEVELOPMENT
Activities carried out by the Pharmacy Practice and Development is focused on giving the best pharmaceutical care services in line with current needs. Training modules and guidelines will be updated to standardise and enhance the quality of pharmaceutical care. In addition, Home Medication Review services will be expanded to enable a continous care from health facilities to patients’ homes.
The strategy to strengthen quality use of medicines is by extending the Know Your Medicines Ambassadors activities to states. These activities empowers the public towards responsible use of medicines which in turn helps to enhance safe and effective use of medicines.
This division also stresses on having an ecosystem which supports the growth of clinical research through increasing researcher competitiveness as well as dissemination and use of research evidences to improve services. Based on the strategic plan of the National Medicines Policy, this division will focus on activities to ensure continuous supply of safe, effective, cost-effective and quality medicines as well as improve access to information on prices of medicines that is affordable by Malaysians. The year 2013 will involve discussions with stakeholders to achieve this objective. To ensure pharmacists are competent and meet the needs of the pharmaceutical industry, several measures are being proposed which is to strengthen monitoring of pharmacy programs in accredited higher education institutions locally and abroad as well as the liberalisation of provisional registered pharmacists’ training at gazetted private facilities.
HALATUJU WAY FORWARD
45PROGRAM FARMASI / PHARMACY PROGRAMME
LAPORAN TAHUNANANNUAL REPORT 2012
industri farmaseutikal, beberapa langkah telah dicadangkan seperti memantapkan pemantauan program farmasi di institusi pengajian tinggi tempatan dan luar negara yang memenuhi akreditasi yang ditetapkan serta liberalisasi latihan ahli farmasi pendaftaran bersyarat di fasiliti swasta yang diwartakan.
UBAT-UBATAN SUBSTANDARD DAN PALSU ATAU LANCUNG (SSFFC)
Bahagian Penguatkuasaan Farmasi akan terus berusaha untuk memastikan semua produk farmaseutikal, tradisional, suplemen kesihatan dan kosmetik dalam pasaran adalah sah dari segi pendaftaran dan notifikasinya. Masalah ubat-ubatan substandard dan palsu atau lancung atau yang diistilahkan oleh WHO sebagai SSFFC, memberi kesan kepada industri farmaseutikal negara. Peningkatan kerjasama antara semua agensi dalam mencari pendekatan terbaik untuk bertindak balas kepada gejala produk SSFFC dan mencegah daripada mencerobohi rantaian pengedaran serta mengelakkan penyusupan ke pasaran negara kita adalah penting demi untuk memastikan pembuatan, pengedaran dan penjualan produk SSFFC dapat dihalang sebelum ianya menjadi masalah yang membahayakan kesihatan masyarakat pengguna dan memberi kesan ke atas kredibiliti perkhidmatan kesihatan.
RANG UNDANG-UNDANG FARMASI (RUUF)
Bahagian Penguatkuasa Farmasi akan menyelaras penyediaan peraturan, arahan dan garis panduan di bawah Rang Undang-Undang Farmasi (RUUF) untuk memastikan akta ini dapat diimplementasikan sebaik sahaja ianya diluluskan di parlimen.
SUBSTANDARD/ SPURIOUS/ FALSELY-LABELLED/ FALSIFIED/ COUNTERFEIT MEDICINES (SSFFC)
Pharmacy Enforcement Division will continue to ensure that pharmaceutical, traditional, health supplements and cosmetic products that are available in the market are genuine in terms of registration and notification. Problem of substandard/ spurious/ falsely-labeled/ falsified/ counterfeit or named by the WHO as SSFFC, gives an impact on the country’s pharmaceutical industry. Increased cooperation between all agencies in finding the best approach for responding to the phenomenon of SSFFC and preventing it’s encroachment into supply chain and market penetration in our country is important in order to ensure that the manufacture, supply and sale of SSFFC products can be curbed before it becomes a problem that endanger the public health and gives an impact on the credibility of health services.
NEW PHARMACY BILL
Enforcement Division will coordinate the preparation of regulations, directives and guidelines under the New Pharmacy Bill to ensure that this act can be implemented once it is approved in parliament.
46 PROGRAM FARMASI / PHARMACY PROGRAMME
LAPORAN TAHUNANANNUAL REPORT2012
BIRO PENGAWALAN FARMASEUTIKAL KEBANGSAAN
Garis Panduan Pendaftaran Produk (DRGD), dokumen rujukan bagi proses pendaftaran produk, akan sentiasa dikemaskini dengan maklumat berkaitan kawalan kualiti, pemeriksaan premis dan perlesenan. Mulai tahun 2013, pengkelasan bagi produk-produk yang berada di bawah kategori interfasa Makanan-Ubat akan dilaksanakan oleh BPFK.
Selain itu, BPFK akan menjalankan pemeriksaan pusat kajian Bio-equivalance (BE) luar negara. Produk berdaftar generik yang sedia ada dalam pasaran telah diberikan sehingga 1 Januari 2014 untuk mematuhi keperluan BE.
Sebagai langkah menambahbaik perkhidmatan yang diberikan, kertas cadangan untuk implementasi Malaysian Variation Guideline (MVG) akan dibentangkan pada tahun 2013. Selain itu, satu latihan kepada pihak industri farmaseutikal mengenai MVG akan diadakan.
BPFK akan terus berusaha menerokai bidang ujian analitikal bahan farmaseutikal aktif, vaksin dan produk bioteknologi. Metodologi untuk pengesanan sebatian penanda dalam spesies tumbuhan yang digunakan dalam produk perubatan semulajadi akan dibangunkan selain bekerjasama dengan institusi kerajaan lain dalam bidang penyelidikan bahan toksik dan sebatian penanda negatif dalam bahan mentah dan produk perubatan semula jadi.
BPFK yakin untuk menjadi ahli bukan OECD yang patuh kepada sistem Mutual Acceptance of Data (MAD), di mana Malaysia akan menjadi salah satu hub kajian bukan klinikal di Asia Tenggara.
BPFK berhasrat untuk mengadakan lebih banyak kerjasama dengan agensi-agensi regulatori luar negara
NATIONAL PHARMACEUTICAL CONTROL BUREAU
The Drug Registration Guidance Document (DRGD), the reference guide for product registration, will be regularly updated with information pertaining to quality control, inspection and licensing. Starting from 2013, the classification of products under the Food-Drug interphase category will be done by NPCB.
Besides that, NPCB will be conducting inspection of overseas Bio-equivalence (BE) centres. Existing registered generic products in the market have been given until 1st January 2014 to comply with the BE requirements.
In order to improve the services provided, the proposal for implementation of the Malaysian Variation Guideline (MVG) will be presented in 2013. Besides that, a training course on the MVG for the pharmaceutical industry will be held.
NPCB will venture into analytical testing of Active Pharmaceutical Ingredients (APIs), vaccines and biotechnology products. Methodologies for detection of marker compound in plant species used in natural medicinal products will be developed as well as collaboration with other government institutions in research of toxic substances and negative marker compound in natural raw materials and products.
NPCB is positive in being a non-OECD member adhering to the Mutual Acceptance of Data (MAD) System, where Malaysia will be one of the non-clinical studies hubs in Southeast Asia.
NPCB looks forward to having more collaboration with other international regulatory agencies through Technical Bilateral Meetings and formal Memorandum of Understanding (MoU). NPCB will take part in the development of ASEAN Non-Pharmacopeial Analytical Method under ASEAN Working Group on Pharmaceutical
47PROGRAM FARMASI / PHARMACY PROGRAMME
LAPORAN TAHUNANANNUAL REPORT 2012
melalui mesyuarat teknikal dua-hala dan Memorandum of Understanding (MoU). BPFK akan mengambil bahagian dalam pembangunan ‘ASEAN Non-Pharmacopoeia Analytical Method under ASEAN Working Group on Pharmaceutical Development (AWGPD)’ yang memberi tumpuan kepada pengesanan bahan campurpalsu farmaseutikal di dalam produk semulajadi
Development (AWGPD) focusing on the detection of pharmaceutical adulterants in traditional medicines.
KESIMPULAN SUMMARY
Empat aktiviti utama di bawah Program Farmasi seperti Dasar dan Pengurusan Farmasi, Amalan dan Perkembangan Farmasi, Penguatkuasaan Farmasi dan Biro Pengawalan Farmaseutikal Kebangsaan telah mencapai kejayaan dalam pelaksanaannya pada tahun 2012. Aktiviti-aktiviti sedia ada dan perkhidmatan farmasi yang disediakan akan diperkukuhkan bagi memastikan hanya produk farmaseutikal dan kesihatan yang berkualiti, selamat dan berkesan disediakan dan mampu milik kepada orang ramai dan digunakan secara berkualiti.
The four main activities such as Policy and Pharmacy Management, Pharmacy Practice and Development, Pharmacy Enforcement and National Pharmaceutical Control Bureau (NPCB) under the Pharmacy Programme were successfully carried out in year 2012. Existing activities and pharmacy services provided will be strengthened to ensure only quality, safe and efficacious pharmaceutical and health products are available and affordable to the public and use of medicines is judicious.
48 PROGRAM FARMASI / PHARMACY PROGRAMME
LAPORAN TAHUNANANNUAL REPORT2012
JAWATANKUASA EDITORIAL EDITORIAL COMMITTEE
Penasihat | Advisor : Dato’ Eisah binti A. RahmanPengerusi | Chairperson : Dr. Nour Hanah binti OthmanAhli | Members : Puan Wan Mohaina binti Wan Mohammad : Puan Rohaida binti Zakaria : Cik Siti Hufaidah binti Suhimi : En. Kamaruddin bin Ahmad : Puan Kon Ee Wen : Cik Syuhadah Mohamed Hassan : En. Muhammad Syafiq bin Saleh : En. Soon Thien Loong : Cik Yap Fei Ting : En. Muhammad Mawardi bin Zakaria
Jawatankuasa Editorial ingin merakamkan setinggi-tinggi penghargaan kepada semua yang terlibat dalam memberi sumbangan dan kerjasama sama ada secara langsung atau tidak langsung dalam menjayakan penerbitan laporan tahunan Bahagian Perkhidmatan Farmasi 2012 ini.
The Editorial Committee would like to acknowledge all sections of the Pharmaceutical Services Division, Ministry of Health Malaysia for their contribution towards the production of the 2012 Annual Report.
LAMPIRAN
ANNEXURE
50 PROGRAM FARMASI / PHARMACY PROGRAMME
LAPORAN TAHUNANANNUAL REPORT2012
LAMPIRAN
1 | L a p o r a n T a h u n a n 2 0 1 2
STATISTIK | STATISTIC
Jadual 1: Pencapaian Perkhidmatan Farmasi Klinikal & Teknikal
Table1: Clinical & Technical Pharmacy Services Achievements
Bil.
No.
Jenis Perkhidmatan
Types of Services
Pencapaian(2012)
Achievements(2012)
1
Perkhidmatan Kaunseling
Ubat
Medication Counselling
Services
i. Bilangan pesakit menerima kaunseling
Number of Patients Counselled
Pesakit Dalam | Inpatient
Pesakit Luar | Outpatient
Discaj Wad | Ward Discharge
Pesakit Luar | Outpatient
(Klinik Kesihatan | Health Clinic)
ii. Jumlah pesakit menerima kaunseling
Total number of patients counselled
165,355
224,277
215,571
382,489
987,692
2
Perkhidmatan Farmokinetik
Klinikal
Clinical Pharmacokinetics
Services
i. Bilangan Hospital | Number of Hospitals
ii. Bilangan Kes | Number of Cases
iii. Bilangan Ubat | Number of Drugs
127
104,761
18
3
Perkhidmatan Nutrisi
Parenteral
Parenteral Nutrition
Services
i. Bilangan Hospital | Number of Hospitals
ii. Bilangan Kes | Number of Cases
iii. Bilangan Persediaan | Number of Preparations
39
11,674
96,298
4
Perkhidmatan Admikstur
Intravena
Intravenous Admixture
Services
i. Bilangan Hospital | Number of Hospitals
ii. Bilangan Persediaan | Number of Preparations
24
207,138
5
Perkhidmatan Farmasi
Onkologi
Oncology Pharmacy
Services
i. Bilangan Hospital | Number of Hospitals
ii. Bilangan Kes | Number of Cases
iii. Bilangan Persediaan| Number of Preparations
54
97,328
233,171
6
Perkhidmatan
Pendispensan Ubat Pesakit
Luar
Outpatient Drug Dispensing
Services
A. Hospital | Hospitals
i. Bilangan preskripsi diterima
Number of prescriptions received
ii. Bilangan preskripsi diintervensi
Number of Prescriptions Intervened
B. Klinik Kesihatan | Health Clinics
iii. Bilangan preskripsi diterima
Number of Prescriptions Received
iv. Bilangan Preskripsi diintervensi
Number of Prescriptions Intervened
19,101,188
18,040,774
28,438,975
20,246,619
LAMPIRAN
2 | L a p o r a n T a h u n a n 2 0 1 2
Bil.
No.
Jenis Perkhidmatan
Types of Services
Pencapaian(2012)
Achievements(2012)
C. Jumlah preskripsi diterima
Total number of Prescriptions Received
D. Jumlah preskripsi diintervensi
Total number of Prescriptions Intervened
47,540,163
38,287,393
7
Medication Therapy
Adherence Clinic
Medication Therapy
Adherence Clinic
i. Bilangan MTAC Fasiliti
Number of Facilities offering MTAC Services
ii. Bilangan Pesakit dalam perkhidmatan MTAC
Number of patients recruited into MTAC
Services
662
23,446
8 Methadone
Methadone
Fasiliti Pendispensan Methadone
Methadone Dispensing Facilities
i. Hospital | Hospitals
ii. Klinik Kesihatan | Health Clinics
49
203
9
Perkhidmatan Farmasi
Nuklear
Nuclear Pharmacy Services
i. Bilangan Hospital | Number of Hospitals
ii. Bilangan persediaan kit-based
Number of Kit-Based Preparations
iii. Bilangan persediaan 18F-FDG
Number of 18F-FDG Preparations
5
9,350
235
10 Sistem Unit Dos
Unit Dose System
i. Bilangan Hospital Negeri & HKL
Number of State Hospitals & HKL
ii. Bilangan Hospital Pakar Major
Number of Major Specialists’ Hospitals
iii. Bilangan Hospital Pakar Minor & Hospital
Bukan Pakar
Number of Minor Specialists’ & Non
Specialists’ Hospitals
13
24
37
51PROGRAM FARMASI / PHARMACY PROGRAMME
LAPORAN TAHUNANANNUAL REPORT 2012LAMPIRAN
2 | L a p o r a n T a h u n a n 2 0 1 2
Bil.
No.
Jenis Perkhidmatan
Types of Services
Pencapaian(2012)
Achievements(2012)
C. Jumlah preskripsi diterima
Total number of Prescriptions Received
D. Jumlah preskripsi diintervensi
Total number of Prescriptions Intervened
47,540,163
38,287,393
7
Medication Therapy
Adherence Clinic
Medication Therapy
Adherence Clinic
i. Bilangan MTAC Fasiliti
Number of Facilities offering MTAC Services
ii. Bilangan Pesakit dalam perkhidmatan MTAC
Number of patients recruited into MTAC
Services
662
23,446
8 Methadone
Methadone
Fasiliti Pendispensan Methadone
Methadone Dispensing Facilities
i. Hospital | Hospitals
ii. Klinik Kesihatan | Health Clinics
49
203
9
Perkhidmatan Farmasi
Nuklear
Nuclear Pharmacy Services
i. Bilangan Hospital | Number of Hospitals
ii. Bilangan persediaan kit-based
Number of Kit-Based Preparations
iii. Bilangan persediaan 18F-FDG
Number of 18F-FDG Preparations
5
9,350
235
10 Sistem Unit Dos
Unit Dose System
i. Bilangan Hospital Negeri & HKL
Number of State Hospitals & HKL
ii. Bilangan Hospital Pakar Major
Number of Major Specialists’ Hospitals
iii. Bilangan Hospital Pakar Minor & Hospital
Bukan Pakar
Number of Minor Specialists’ & Non
Specialists’ Hospitals
13
24
37
LAMPIRAN
2 | L a p o r a n T a h u n a n 2 0 1 2
Bil.
No.
Jenis Perkhidmatan
Types of Services
Pencapaian(2012)
Achievements(2012)
C. Jumlah preskripsi diterima
Total number of Prescriptions Received
D. Jumlah preskripsi diintervensi
Total number of Prescriptions Intervened
47,540,163
38,287,393
7
Medication Therapy
Adherence Clinic
Medication Therapy
Adherence Clinic
i. Bilangan MTAC Fasiliti
Number of Facilities offering MTAC Services
ii. Bilangan Pesakit dalam perkhidmatan MTAC
Number of patients recruited into MTAC
Services
662
23,446
8 Methadone
Methadone
Fasiliti Pendispensan Methadone
Methadone Dispensing Facilities
i. Hospital | Hospitals
ii. Klinik Kesihatan | Health Clinics
49
203
9
Perkhidmatan Farmasi
Nuklear
Nuclear Pharmacy Services
i. Bilangan Hospital | Number of Hospitals
ii. Bilangan persediaan kit-based
Number of Kit-Based Preparations
iii. Bilangan persediaan 18F-FDG
Number of 18F-FDG Preparations
5
9,350
235
10 Sistem Unit Dos
Unit Dose System
i. Bilangan Hospital Negeri & HKL
Number of State Hospitals & HKL
ii. Bilangan Hospital Pakar Major
Number of Major Specialists’ Hospitals
iii. Bilangan Hospital Pakar Minor & Hospital
Bukan Pakar
Number of Minor Specialists’ & Non
Specialists’ Hospitals
13
24
37
LAMPIRAN
3 | L a p o r a n T a h u n a n 2 0 1 2
Rajah 1: Nisbah Ahli Farmasi : Populasi (2005-2020)
Figure 1: Pharmacists : Population Ratio (2005-2020)
52904871
45334199
38783592
3282 29462662 2437 2249
2087 1952 1834 1731 1643
0
1000
2000
3000
4000
5000
6000
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020
Nisbah Ahli Farmasi: PopulasiPharmacists : Population Ratio
52 PROGRAM FARMASI / PHARMACY PROGRAMME
LAPORAN TAHUNANANNUAL REPORT2012
L
AM
PIR
AN
4
| L
ap
or
an
T
ah
un
an
2
01
2
Jad
ual
2:
Sen
ara
i U
niv
ers
iti d
i d
ala
m N
eg
ara
ya
ng
men
aw
ark
an
Pro
gra
m I
jazah
Farm
asi
(20
12
)
Tab
le 2
: L
ist
of
un
ivers
itie
s o
fferi
ng
Ph
arm
ac
y P
rog
ram
me c
ou
rses
(20
12)
*Fu
lly r
eco
gn
ised
by P
ha
rmac
y B
oard
Ma
lay
sia
Bil
.
No
. In
sti
tus
i |
Insti
tuti
on
P
rog
ram
| P
rog
ram
me
1.
Un
ive
rsiti S
ain
s M
ala
ysia
| U
niv
ers
ity o
f S
ain
s M
ala
ysia
S
arj
an
a M
uda
Fa
rma
si (k
ep
ujia
n)*
| B
ache
lor
of
Ph
arm
acy (
Hon
s)*
2.
Un
ive
rsiti K
eb
an
gsa
an
Mala
ysia
N
atio
na
l U
niv
ers
ity o
f M
ala
ysia
S
arj
an
a M
uda
Fa
rma
si (k
ep
ujia
n)*
|
Ba
ch
elo
r of
Pha
rmacy (
Ho
ns)*
3.
Un
ive
rsiti M
ala
ya | U
niv
ers
ity o
f M
ala
ya
S
arj
an
a M
uda
Fa
rma
si (k
ep
ujia
n)*
|
Ba
ch
elo
r of
Pha
rmacy (
Ho
ns)*
4.
Un
ive
rsiti T
ekn
olo
gi M
AR
A
Un
ive
rsity o
f T
ech
no
log
y M
AR
A
Sarj
an
a M
uda
Fa
rma
si (k
ep
ujia
n)*
| B
ache
lor
of
Ph
arm
acy (
Hon
s)*
5.
Un
ive
rsiti Is
lam
An
tara
ba
ng
sa
Ma
laysia
(U
IAM
) In
tern
atio
na
l Is
lam
ic U
niv
ers
ity M
ala
ysia
(II
UM
) S
arj
an
a M
uda
Fa
rma
si (k
ep
ujia
n)*
| B
ache
lor
of
Ph
arm
acy (
Hon
s)*
6.
Un
ive
rsiti U
CS
I | U
CS
I U
niv
ers
ity
Sarj
an
a M
ud
a F
arm
asi (k
ep
ujia
n)*
| B
ache
lor
of
Ph
arm
acy (
Hon
s)*
7.
Un
ive
rsiti P
eru
bata
n A
nta
rab
an
gsa
Ma
laysia
(IM
U)
Inte
rnatio
na
l M
ed
ical U
niv
ers
ity (
IMU
)
Sarj
an
a F
arm
asi (P
rog
ram
Be
rke
mb
ar
bers
am
a S
trath
cly
de U
niv
ers
iti,
UK
2 ½
+1
)*
Ma
ste
r of
Pha
rmacy (
twin
ing
2 ½
+ 1
with U
niv
ers
ity S
tra
thcly
de
, U
K)
*
Sarj
an
a F
arm
asi (P
rog
ram
Be
rkem
ba
r b
ers
am
a S
trath
cly
de U
niv
ers
iti,
UK
2 +
2)*
M
aste
r of
Pha
rmacy (
twin
ing
2 +
2 w
ith
Un
ivers
ity S
tra
thcly
de
, U
K)
*
Sarj
an
a M
ud
a F
arm
asi (k
ep
ujia
n)*
Ba
ch
elo
r o
f P
ha
rma
cy (
Ho
ns)*
L
AM
PIR
AN
4
| L
ap
or
an
T
ah
un
an
2
01
2
Jad
ual
2:
Sen
ara
i U
niv
ers
iti d
i d
ala
m N
eg
ara
ya
ng
men
aw
ark
an
Pro
gra
m I
jazah
Farm
asi
(20
12
)
Tab
le 2
: L
ist
of
un
ivers
itie
s o
fferi
ng
Ph
arm
ac
y P
rog
ram
me c
ou
rses
(20
12)
*Fu
lly r
eco
gn
ised
by P
ha
rmac
y B
oard
Ma
lay
sia
Bil
.
No
. In
sti
tus
i |
Insti
tuti
on
P
rog
ram
| P
rog
ram
me
1.
Un
ive
rsiti S
ain
s M
ala
ysia
| U
niv
ers
ity o
f S
ain
s M
ala
ysia
S
arj
an
a M
uda
Fa
rma
si (k
ep
ujia
n)*
| B
ache
lor
of
Ph
arm
acy (
Hon
s)*
2.
Un
ive
rsiti K
eb
an
gsa
an
Mala
ysia
N
atio
na
l U
niv
ers
ity o
f M
ala
ysia
S
arj
an
a M
uda
Fa
rma
si (k
ep
ujia
n)*
|
Ba
ch
elo
r of
Pha
rmacy (
Ho
ns)*
3.
Un
ive
rsiti M
ala
ya | U
niv
ers
ity o
f M
ala
ya
S
arj
an
a M
uda
Fa
rma
si (k
ep
ujia
n)*
|
Ba
ch
elo
r of
Pha
rmacy (
Ho
ns)*
4.
Un
ive
rsiti T
ekn
olo
gi M
AR
A
Un
ive
rsity o
f T
ech
no
log
y M
AR
A
Sarj
an
a M
uda
Fa
rma
si (k
ep
ujia
n)*
| B
ache
lor
of
Ph
arm
acy (
Hon
s)*
5.
Un
ive
rsiti Is
lam
An
tara
ba
ng
sa
Ma
laysia
(U
IAM
) In
tern
atio
na
l Is
lam
ic U
niv
ers
ity M
ala
ysia
(II
UM
) S
arj
an
a M
uda
Fa
rma
si (k
ep
ujia
n)*
| B
ache
lor
of
Ph
arm
acy (
Hon
s)*
6.
Un
ive
rsiti U
CS
I | U
CS
I U
niv
ers
ity
Sarj
an
a M
ud
a F
arm
asi (k
ep
ujia
n)*
| B
ache
lor
of
Ph
arm
acy (
Hon
s)*
7.
Un
ive
rsiti P
eru
bata
n A
nta
rab
an
gsa
Ma
laysia
(IM
U)
Inte
rnatio
na
l M
ed
ical U
niv
ers
ity (
IMU
)
Sarj
an
a F
arm
asi (P
rog
ram
Be
rke
mb
ar
bers
am
a S
trath
cly
de U
niv
ers
iti,
UK
2 ½
+1
)*
Ma
ste
r of
Pha
rmacy (
twin
ing
2 ½
+ 1
with U
niv
ers
ity S
tra
thcly
de
, U
K)
*
Sarj
an
a F
arm
asi (P
rog
ram
Be
rkem
ba
r b
ers
am
a S
trath
cly
de U
niv
ers
iti,
UK
2 +
2)*
M
aste
r of
Pha
rmacy (
twin
ing
2 +
2 w
ith
Un
ivers
ity S
tra
thcly
de
, U
K)
*
Sarj
an
a M
ud
a F
arm
asi (k
ep
ujia
n)*
Ba
ch
elo
r o
f P
ha
rma
cy (
Ho
ns)*
L
AM
PIR
AN
5
| L
ap
or
an
T
ah
un
an
2
01
2
Bil
.
No
. In
sti
tus
i |
Insti
tuti
on
P
rog
ram
| P
rog
ram
me
8.
AIM
ST
Un
ivers
iti | A
IMS
T U
niv
ers
ity
Sarj
an
a M
uda
Fa
rma
si (k
ep
ujia
n)*
| B
ache
lor
of
Ph
arm
acy (
Hon
s)*
9.
Un
ive
rsiti N
ott
ing
ha
m K
am
pu
s M
ala
ysia
(U
NM
C)
Un
ive
rsity N
ott
ing
ha
m M
ala
ysia
Ca
mp
us (
UN
MC
)
Sarj
an
a F
arm
asi*
(2+
2 s
am
a d
eng
an
pro
gra
m N
ott
ing
ha
m U
niv
ers
iti)
Ma
ste
r in
Pha
rmacy 2
+2
sim
ilar
* p
rog
ram
me
of
Un
ive
rsity N
ott
ing
ha
m,
UK
10
. K
ole
j U
niv
ers
iti S
ain
s P
eru
ba
tan
Cyb
erj
aya
(C
UC
MS
) C
ybe
rja
ya U
niv
ers
ity C
olle
ge
of
Me
dic
al S
cie
nce
s
(CU
CM
S)
S
arj
an
a M
ud
a F
arm
asi (k
ep
ujia
n)*
| B
ache
lor
of
Ph
arm
acy (
Hon
s)*
11
.
Un
ive
rsiti A
sia
Me
tro
po
lita
n (
AM
U)
(Ko
lej U
niv
ers
iti S
ain
s K
esih
ata
n M
aste
rskill
) A
sia
Metr
op
olit
an
Un
ive
rsity (
AM
U)
(Ma
ste
rskill
Un
ive
rsity C
olle
ge
of
He
alth
Scie
nce
s)
Sarj
an
a M
ud
a F
arm
asi (k
ep
ujia
n)
4+
0 d
en
ga
n L
a T
rop
e U
niv
ers
iti,
Austr
alia
B
ach
elo
r of
Ph
arm
acy (
Hon
s)
4+
0 w
ith
Univ
ers
ity L
a T
rop
e,
Au
str
alia
12
. U
niv
ers
iti M
ana
ge
me
nt
& S
cie
nce
(M
SU
)
Man
ag
em
en
t &
Scie
nce
Un
ive
rsity (
MS
U)
Sarj
an
a M
ud
a F
arm
asi (k
ep
ujia
n)*
| B
ache
lor
of
Ph
arm
acy (
Hon
s)*
13
. U
niv
ers
iti S
EG
I | S
EG
I U
niv
ers
ity
Sarj
an
a F
arm
asi (P
rog
ram
Be
rke
mb
ar
bers
am
a S
un
de
rla
nd
Un
ive
rsiti,
UK
2+
2)
Ma
ste
r of
Pha
rmacy (
2+
2 tw
inn
ing w
ith U
niv
ers
ity o
f S
und
erl
an
d,
UK
)
14
. U
niv
ers
iti M
ona
sh
Ka
mp
us M
ala
ysia
M
on
ash
Un
ive
rsity M
ala
ysia
Cam
pu
s
Sarj
an
a M
ud
a F
arm
asi (k
ep
ujia
n)
sam
a d
en
gan
pro
gra
m U
niv
ers
iti
Mo
na
sh
, A
ustr
alia
B
ach
elo
r of
Ph
arm
acy (
Hon
s)
sim
ilar
pro
gra
mm
e o
f M
on
ash
Un
ive
rsity,
Austr
alia
15
. U
niv
ers
iti M
AH
SA
| M
AH
SA
Un
ive
rsity
Sarj
an
a M
ud
a F
arm
asi (k
ep
ujia
n)
| B
ache
lor
of
Ph
arm
acy (
Hon
s)
53PROGRAM FARMASI / PHARMACY PROGRAMME
LAPORAN TAHUNANANNUAL REPORT 2012
L
AM
PIR
AN
5
| L
ap
or
an
T
ah
un
an
2
01
2
Bil
.
No
. In
sti
tus
i |
Insti
tuti
on
P
rog
ram
| P
rog
ram
me
8.
AIM
ST
Un
ivers
iti | A
IMS
T U
niv
ers
ity
Sarj
an
a M
uda
Fa
rma
si (k
ep
ujia
n)*
| B
ache
lor
of
Ph
arm
acy (
Hon
s)*
9.
Un
ive
rsiti N
ott
ing
ha
m K
am
pu
s M
ala
ysia
(U
NM
C)
Un
ive
rsity N
ott
ing
ha
m M
ala
ysia
Ca
mp
us (
UN
MC
)
Sarj
an
a F
arm
asi*
(2+
2 s
am
a d
eng
an
pro
gra
m N
ott
ing
ha
m U
niv
ers
iti)
Ma
ste
r in
Pha
rmacy 2
+2
sim
ilar
* p
rog
ram
me
of
Un
ive
rsity N
ott
ing
ha
m,
UK
10
. K
ole
j U
niv
ers
iti S
ain
s P
eru
ba
tan
Cyb
erj
aya
(C
UC
MS
) C
ybe
rja
ya U
niv
ers
ity C
olle
ge
of
Me
dic
al S
cie
nce
s
(CU
CM
S)
S
arj
an
a M
ud
a F
arm
asi (k
ep
ujia
n)*
| B
ache
lor
of
Ph
arm
acy (
Hon
s)*
11
.
Un
ive
rsiti A
sia
Me
tro
po
lita
n (
AM
U)
(Ko
lej U
niv
ers
iti S
ain
s K
esih
ata
n M
aste
rskill
) A
sia
Metr
op
olit
an
Un
ive
rsity (
AM
U)
(Ma
ste
rskill
Un
ive
rsity C
olle
ge
of
He
alth
Scie
nce
s)
Sarj
an
a M
ud
a F
arm
asi (k
ep
ujia
n)
4+
0 d
en
ga
n L
a T
rop
e U
niv
ers
iti,
Austr
alia
B
ach
elo
r of
Ph
arm
acy (
Hon
s)
4+
0 w
ith
Univ
ers
ity L
a T
rop
e,
Au
str
alia
12
. U
niv
ers
iti M
ana
ge
me
nt
& S
cie
nce
(M
SU
)
Man
ag
em
en
t &
Scie
nce
Un
ive
rsity (
MS
U)
Sarj
an
a M
ud
a F
arm
asi (k
ep
ujia
n)*
| B
ache
lor
of
Ph
arm
acy (
Hon
s)*
13
. U
niv
ers
iti S
EG
I | S
EG
I U
niv
ers
ity
Sarj
an
a F
arm
asi (P
rog
ram
Be
rke
mb
ar
bers
am
a S
un
de
rla
nd
Un
ive
rsiti,
UK
2+
2)
Ma
ste
r of
Pha
rmacy (
2+
2 tw
inn
ing w
ith U
niv
ers
ity o
f S
und
erl
an
d,
UK
)
14
. U
niv
ers
iti M
ona
sh
Ka
mp
us M
ala
ysia
M
on
ash
Un
ive
rsity M
ala
ysia
Cam
pu
s
Sarj
an
a M
ud
a F
arm
asi (k
ep
ujia
n)
sam
a d
en
gan
pro
gra
m U
niv
ers
iti
Mo
na
sh
, A
ustr
alia
B
ach
elo
r of
Ph
arm
acy (
Hon
s)
sim
ilar
pro
gra
mm
e o
f M
on
ash
Un
ive
rsity,
Austr
alia
15
. U
niv
ers
iti M
AH
SA
| M
AH
SA
Un
ive
rsity
Sarj
an
a M
ud
a F
arm
asi (k
ep
ujia
n)
| B
ache
lor
of
Ph
arm
acy (
Hon
s)
L
AM
PIR
AN
5
| L
ap
or
an
T
ah
un
an
2
01
2
Bil
.
No
. In
sti
tus
i | In
sti
tuti
on
P
rog
ram
| P
rog
ram
me
8.
AIM
ST
Un
ivers
iti | A
IMS
T U
niv
ers
ity
Sarj
an
a M
uda
Fa
rma
si (k
ep
ujia
n)*
| B
ache
lor
of
Ph
arm
acy (
Hon
s)*
9.
Un
ive
rsiti N
ott
ing
ha
m K
am
pu
s M
ala
ysia
(U
NM
C)
Un
ive
rsity N
ott
ing
ha
m M
ala
ysia
Ca
mp
us (
UN
MC
)
Sarj
an
a F
arm
asi*
(2+
2 s
am
a d
eng
an
pro
gra
m N
ott
ing
ha
m U
niv
ers
iti)
Ma
ste
r in
Pha
rmacy 2
+2
sim
ilar
* p
rog
ram
me
of
Un
ive
rsity N
ott
ing
ha
m,
UK
10
. K
ole
j U
niv
ers
iti S
ain
s P
eru
ba
tan
Cyb
erj
aya
(C
UC
MS
) C
ybe
rja
ya U
niv
ers
ity C
olle
ge
of
Me
dic
al S
cie
nce
s
(CU
CM
S)
S
arj
an
a M
ud
a F
arm
asi (k
ep
ujia
n)*
| B
ache
lor
of
Ph
arm
acy (
Hon
s)*
11
.
Un
ive
rsiti A
sia
Me
tro
po
lita
n (
AM
U)
(Ko
lej U
niv
ers
iti S
ain
s K
esih
ata
n M
aste
rskill
) A
sia
Metr
op
olit
an
Un
ive
rsity (
AM
U)
(Ma
ste
rskill
Un
ive
rsity C
olle
ge
of
He
alth
Scie
nce
s)
Sarj
an
a M
ud
a F
arm
asi (k
ep
ujia
n)
4+
0 d
en
ga
n L
a T
rop
e U
niv
ers
iti,
Austr
alia
B
ach
elo
r of
Ph
arm
acy (
Hon
s)
4+
0 w
ith
Univ
ers
ity L
a T
rop
e,
Au
str
alia
12
. U
niv
ers
iti M
ana
ge
me
nt
& S
cie
nce
(M
SU
)
Man
ag
em
en
t &
Scie
nce
Un
ive
rsity (
MS
U)
Sarj
an
a M
ud
a F
arm
asi (k
ep
ujia
n)*
| B
ache
lor
of
Ph
arm
acy (
Hon
s)*
13
. U
niv
ers
iti S
EG
I | S
EG
I U
niv
ers
ity
Sarj
an
a F
arm
asi (P
rog
ram
Be
rke
mb
ar
bers
am
a S
un
de
rla
nd
Un
ive
rsiti,
UK
2+
2)
Ma
ste
r of
Pha
rmacy (
2+
2 tw
inn
ing w
ith U
niv
ers
ity o
f S
und
erl
an
d,
UK
)
14
. U
niv
ers
iti M
ona
sh
Ka
mp
us M
ala
ysia
M
on
ash
Un
ive
rsity M
ala
ysia
Cam
pu
s
Sarj
an
a M
ud
a F
arm
asi (k
ep
ujia
n)
sam
a d
en
gan
pro
gra
m U
niv
ers
iti
Mo
na
sh
, A
ustr
alia
B
ach
elo
r of
Ph
arm
acy (
Hon
s)
sim
ilar
pro
gra
mm
e o
f M
on
ash
Un
ive
rsity,
Austr
alia
15
. U
niv
ers
iti M
AH
SA
| M
AH
SA
Un
ive
rsity
Sarj
an
a M
ud
a F
arm
asi (k
ep
ujia
n)
| B
ache
lor
of
Ph
arm
acy (
Hon
s)
L
AM
PIR
AN
6
| L
ap
or
an
T
ah
un
an
2
01
2
Bil
.
No
. In
sti
tus
i | In
sti
tuti
on
P
rog
ram
| P
rog
ram
me
16
. U
niv
ers
iti T
aylo
r’s | T
aylo
r’s U
niv
ers
ity
Sarj
an
a M
ud
a F
arm
asi (k
ep
ujia
n)
| B
ache
lor
of
Ph
arm
acy (
Hon
s)
Sarj
an
a F
arm
asi (2
+2
) ke
rjasa
ma
de
ng
an
Ca
rdiff
Univ
ers
iti, U
K
Ma
ste
r of
Pha
rmacy (
2+
2)
in c
olla
bora
tio
n w
ith
Ca
rdiff U
niv
ers
ity, U
K
54 PROGRAM FARMASI / PHARMACY PROGRAMME
LAPORAN TAHUNANANNUAL REPORT2012
L
AM
PIR
AN
7
| L
ap
or
an
T
ah
un
an
2
01
2
Tre
n P
en
cap
aia
n K
PI
200
9-2
01
2
(Tie
r 1
, 2
dan
3)
KP
I P
erf
orm
an
ce T
ren
d 2
00
9-2
01
2 (
Tie
r 1,
2 a
nd
3)
A. A
MA
LAN
DA
N P
ERKE
MBA
NG
AN
FA
RMA
SI |
PHA
RMA
CY
PRA
CTIC
E A
ND
DEVE
LOPM
ENT
BIL
. N
o.
KP
I K
PI
PE
NC
AP
AIA
N A
CH
IEV
EM
EN
TS
20
09
201
0
201
1
20
12
1.
B
ilan
ga
n h
osp
ital
da
n k
linik
kesih
ata
n y
an
g
me
na
wa
rka
n S
iste
m T
em
uja
nji
me
ng
am
bil
ub
at
di F
arm
asi
(Con
toh
: S
MS
&
Am
bil,
T
ele
fon
&A
mb
il,
Farm
asi
Pa
nd
u L
alu
, U
MP
1 M
ala
ysia
, dll)
ke
pa
da
p
esakit
ya
ng
m
en
erim
a
raw
ata
n
jan
gka p
an
jan
g
Nu
mb
er
of
Hosp
ita
ls
an
d
Hea
lth
C
linic
s
Off
eri
ng
App
oin
tme
nt
Syste
m f
or
obta
inin
g
refill
me
dic
ation
s (
eg
. S
MS
& T
ake
, C
all
&
Take
, D
rive T
hru
Pha
rmacy,
Dru
g T
hro
ug
h
Posta
l S
erv
ice
1M
ala
ysia
etc
)
87
ho
spita
l &
3
8 k
linik
ke
sih
ata
n
8
7 h
osp
ita
ls &
38
he
alth
clin
ics
S
AS
AR
AN
T
AR
GE
T:
60
ho
spita
l &
2
0 k
linik
ke
sih
ata
n
6
0 h
osp
ita
ls &
20
he
alth
clin
ics
13
1 h
ospita
l &
201
klin
ik k
esih
ata
n
1
31
ho
spita
ls &
2
01
he
alth c
linic
s
S
AS
AR
AN
T
AR
GE
T:
130
ho
sp
ital &
60
klin
ik k
esih
ata
n
1
30
ho
sp
itals
&
60
he
alth
clin
ics
386
klin
ik k
esih
ata
n
3
86
he
alth c
linic
s
S
AS
AR
AN
T
AR
GE
T:
380
klin
ik k
esih
ata
n
3
80
he
alth c
linic
s
46
5 k
linik
kesih
ata
n
46
5 h
ea
lth
clin
ics
S
AS
AR
AN
T
AR
GE
T:
45
0 k
linik
kesih
ata
n
45
0 h
ea
lth
clin
ics
2.
*P
era
tus
pre
skrip
si
did
isp
en
s
dala
m
tem
po
h 3
0 m
init
Cata
tan
: *M
ula
i 2010
, d
ipin
da
dari k
enyata
an a
sal:
“Pera
tus
Kaunte
r F
arm
asi
KK
M
yang
Berjaya
Mend
ispens U
bat
da
lam
T
em
poh 30 M
init S
ele
pas
Menerim
a P
reskripsi”.
*Perc
en
tag
e
of
pre
scri
ption
s
dis
pe
nse
d
with
in 3
0 m
inu
tes
No
te:
*Begin
nin
g
2010,
am
ended
from
th
e
orig
ina
l sta
tem
ent:
Perc
enta
ge
of
pharm
acy counte
rs
that
managed
to
dis
pense m
edic
atio
ns w
ithin
30 m
inute
s
92
.91
% k
au
nte
r fa
rma
si
9
2.9
1%
ph
arm
acy
co
unte
rs
S
AS
AR
AN
T
AR
GE
T:
80
%
kau
nte
r fa
rma
si
8
0%
ph
arm
acy
co
unte
rs
96
.6%
pre
skri
psi
9
6.6
% p
rescrip
tio
ns
S
AS
AR
AN
T
AR
GE
T:
10
0%
pre
skrip
si
10
0%
pre
scri
ptio
ns
96
.27
% p
reskrip
si
9
6.2
7%
pre
scri
ption
s
S
AS
AR
AN
T
AR
GE
T:
10
0%
pre
skrip
si
10
0%
pre
scri
ptio
ns
95.2
9%
pre
skri
psi
9
5.2
9%
p
rescri
ptio
ns
S
AS
AR
AN
T
AR
GE
T:
95
% p
reskri
psi
95%
pre
scri
ption
s
L
AM
PIR
AN
8
| L
ap
or
an
T
ah
un
an
2
01
2
BIL
. N
o.
KP
I K
PI
PE
NC
AP
AIA
N A
CH
IEV
EM
EN
TS
20
09
201
0
201
1
20
12
3.
P
era
tus
fasili
ti
farm
asi
ya
ng
m
ew
uju
dka
n
MT
AC
C
ata
tan
:
1:
Bila
ngan H
P berk
ura
ng daripada 40 kepada 38
sete
lah p
engecualia
n d
ibuat
bag
i H
ospita
l M
esra
Bukit
Padang d
an H
osp
ital Q
ueen E
liza
beth
II
2 :
Peru
bahan s
asara
n b
agi
suku t
ahun t
era
khir d
gn
mengu
bah
krite
ria
pe
lapora
n
dengan
han
ya
mengam
bil
kira
KK
ya
ng
mem
punya
i 2
Pegaw
ai
Farm
asi (
PF
) sahaja
H
U : H
ospita
l Uta
ma
HP
: H
ospita
l B
erp
akar
HX
P : H
ospita
l Tid
ak B
erp
akar
Perc
en
tag
e
of
ph
arm
acy
facili
tie
s
with
M
TA
C e
sta
blis
hm
en
t N
ote
: 1:
Num
ber
of
SP
reduced f
rom
40 to 3
8 a
fter
exclu
sio
n
of
Mesra
Bukit
Padang H
ospita
l and Q
ueen E
lizabeth
II H
ospital
2:
Change in
targ
et
for
last
quart
er
with
changin
g i
n
report
ing crite
ria due to
hea
lth clin
ics havin
g only
2
pharm
acis
ts p
ers
onnel
MH
: M
ain
Hospita
ls
SP
: S
pecia
list H
ospita
ls
HX
P : H
ospita
l Tid
ak B
erp
akar
NS
P : N
on S
pecia
list H
ospita
ls
10
0%
HU
| M
H
5
3.4
9%
HP
| S
P
S
AS
AR
AN
T
AR
GE
T:
10
0%
HU
| M
H
50
% H
P | S
P
10
0%
HU
| M
H
9
2.1
1%
HP
| S
P
9
9 K
K | H
C
S
AS
AR
AN
T
AR
GE
T:
10
0%
HU
| M
H
7
5%
HP
| S
P
4
0 K
K | H
C
10
0%
HU
| M
H
1
00
% H
P | S
P
2
02
KK
| H
C
S
AS
AR
AN
T
AR
GE
T:
10
0%
HU
| M
H
1
00
% H
P | S
P
1
10
KK
| H
C
10
0%
HU
| M
H
97
% H
P | S
P
(3
7/3
8)1
15
4 K
K2 |
HC
96
% H
XP
| N
SP
SA
SA
RA
N
TA
RG
ET
: 1
00
% H
U | M
H
1
00%
HP
| S
P
2
00
KK
| H
C
10
0%
HX
P | N
SP
L
AM
PIR
AN
8
| L
ap
or
an
T
ah
un
an
2
01
2
BIL
. N
o.
KP
I K
PI
PE
NC
AP
AIA
N A
CH
IEV
EM
EN
TS
20
09
201
0
201
1
20
12
3.
P
era
tus
fasili
ti
farm
asi
ya
ng
m
ew
uju
dka
n
MT
AC
C
ata
tan
:
1:
Bila
ngan H
P berk
ura
ng daripada 40 kepada 38
sete
lah p
engecualia
n d
ibuat
bag
i H
ospita
l M
esra
Bukit
Padang d
an H
osp
ital Q
ueen E
liza
beth
II
2 :
Peru
bahan s
asara
n b
agi
suku t
ahun t
era
khir d
gn
mengu
bah
krite
ria
pe
lapora
n
dengan
han
ya
mengam
bil
kira
KK
ya
ng
mem
punya
i 2
Pegaw
ai
Farm
asi (
PF
) sahaja
H
U : H
ospita
l Uta
ma
HP
: H
ospita
l B
erp
akar
HX
P : H
ospita
l Tid
ak B
erp
akar
Perc
en
tag
e
of
ph
arm
acy
facili
tie
s
with
M
TA
C e
sta
blis
hm
en
t N
ote
: 1:
Num
ber
of
SP
reduced f
rom
40 to 3
8 a
fter
exclu
sio
n
of
Mesra
Bukit
Padang H
ospita
l and Q
ueen E
lizabeth
II H
ospital
2:
Change in
targ
et
for
last
quart
er
with
changin
g i
n
report
ing crite
ria due to
hea
lth clin
ics havin
g only
2
pharm
acis
ts p
ers
onnel
MH
: M
ain
Hospita
ls
SP
: S
pecia
list H
ospita
ls
HX
P : H
ospita
l Tid
ak B
erp
akar
NS
P : N
on S
pecia
list H
ospita
ls
10
0%
HU
| M
H
5
3.4
9%
HP
| S
P
S
AS
AR
AN
T
AR
GE
T:
10
0%
HU
| M
H
50
% H
P | S
P
10
0%
HU
| M
H
9
2.1
1%
HP
| S
P
9
9 K
K | H
C
S
AS
AR
AN
T
AR
GE
T:
10
0%
HU
| M
H
7
5%
HP
| S
P
4
0 K
K | H
C
10
0%
HU
| M
H
1
00
% H
P | S
P
2
02
KK
| H
C
S
AS
AR
AN
T
AR
GE
T:
10
0%
HU
| M
H
1
00
% H
P | S
P
1
10
KK
| H
C
10
0%
HU
| M
H
97
% H
P | S
P
(3
7/3
8)1
15
4 K
K2 |
HC
96
% H
XP
| N
SP
SA
SA
RA
N
TA
RG
ET
: 1
00
% H
U | M
H
1
00%
HP
| S
P
2
00
KK
| H
C
10
0%
HX
P | N
SP
55PROGRAM FARMASI / PHARMACY PROGRAMME
LAPORAN TAHUNANANNUAL REPORT 2012
L
AM
PIR
AN
8
| L
ap
or
an
T
ah
un
an
2
01
2
BIL
. N
o.
KP
I K
PI
PE
NC
AP
AIA
N A
CH
IEV
EM
EN
TS
20
09
201
0
201
1
20
12
3.
P
era
tus
fasili
ti
farm
asi
ya
ng
m
ew
uju
dka
n
MT
AC
C
ata
tan
:
1:
Bila
ngan H
P berk
ura
ng daripada 40 kepada 38
sete
lah p
engecualia
n d
ibuat
bag
i H
ospita
l M
esra
Bukit
Padang d
an H
osp
ital Q
ueen E
liza
beth
II
2 :
Peru
bahan s
asara
n b
agi
suku t
ahun t
era
khir d
gn
mengu
bah
krite
ria
pe
lapora
n
dengan
han
ya
mengam
bil
kira
KK
ya
ng
mem
punya
i 2
Pegaw
ai
Farm
asi (
PF
) sahaja
H
U : H
ospita
l Uta
ma
HP
: H
ospita
l B
erp
akar
HX
P : H
ospita
l Tid
ak B
erp
akar
Perc
en
tag
e
of
ph
arm
acy
facili
tie
s
with
M
TA
C e
sta
blis
hm
en
t N
ote
: 1:
Num
ber
of
SP
reduced f
rom
40 to 3
8 a
fter
exclu
sio
n
of
Mesra
Bukit
Padang H
ospita
l and Q
ueen E
lizabeth
II H
ospital
2:
Change in
targ
et
for
last
quart
er
with
changin
g i
n
report
ing crite
ria due to
hea
lth clin
ics havin
g only
2
pharm
acis
ts p
ers
onnel
MH
: M
ain
Hospita
ls
SP
: S
pecia
list H
ospita
ls
HX
P : H
ospita
l Tid
ak B
erp
akar
NS
P : N
on S
pecia
list H
ospita
ls
10
0%
HU
| M
H
5
3.4
9%
HP
| S
P
S
AS
AR
AN
T
AR
GE
T:
10
0%
HU
| M
H
50
% H
P | S
P
10
0%
HU
| M
H
9
2.1
1%
HP
| S
P
9
9 K
K | H
C
S
AS
AR
AN
T
AR
GE
T:
10
0%
HU
| M
H
7
5%
HP
| S
P
4
0 K
K | H
C
10
0%
HU
| M
H
1
00
% H
P | S
P
2
02
KK
| H
C
S
AS
AR
AN
T
AR
GE
T:
10
0%
HU
| M
H
1
00
% H
P | S
P
1
10
KK
| H
C
10
0%
HU
| M
H
97
% H
P | S
P
(3
7/3
8)1
15
4 K
K2 |
HC
96
% H
XP
| N
SP
SA
SA
RA
N
TA
RG
ET
: 1
00
% H
U | M
H
1
00%
HP
| S
P
2
00
KK
| H
C
10
0%
HX
P | N
SP
L
AM
PIR
AN
8
| L
ap
or
an
T
ah
un
an
2
01
2
BIL
. N
o.
KP
I K
PI
PE
NC
AP
AIA
N A
CH
IEV
EM
EN
TS
20
09
201
0
201
1
20
12
3.
P
era
tus
fasili
ti
farm
asi
ya
ng
m
ew
uju
dka
n
MT
AC
C
ata
tan
:
1:
Bila
ngan H
P berk
ura
ng daripada 40 kepada 38
sete
lah p
engecualia
n d
ibuat
bag
i H
ospita
l M
esra
Bukit
Padang d
an H
osp
ital Q
ueen E
liza
beth
II
2 :
Peru
bahan s
asara
n b
agi
suku t
ahun t
era
khir d
gn
mengu
bah
krite
ria
pe
lapora
n
dengan
han
ya
mengam
bil
kira
KK
ya
ng
mem
punya
i 2
Pegaw
ai
Farm
asi (
PF
) sahaja
H
U : H
ospita
l Uta
ma
HP
: H
ospita
l B
erp
akar
HX
P : H
ospita
l Tid
ak B
erp
akar
Perc
en
tag
e
of
ph
arm
acy
facili
tie
s
with
M
TA
C e
sta
blis
hm
en
t N
ote
: 1:
Num
ber
of
SP
reduced f
rom
40 to 3
8 a
fter
exclu
sio
n
of
Mesra
Bukit
Padang H
ospita
l and Q
ueen E
lizabeth
II H
ospital
2:
Change in
targ
et
for
last
quart
er
with
changin
g i
n
report
ing crite
ria due to
hea
lth clin
ics havin
g only
2
pharm
acis
ts p
ers
onnel
MH
: M
ain
Hospita
ls
SP
: S
pecia
list H
ospita
ls
HX
P : H
ospita
l Tid
ak B
erp
akar
NS
P : N
on S
pecia
list H
ospita
ls
10
0%
HU
| M
H
5
3.4
9%
HP
| S
P
S
AS
AR
AN
T
AR
GE
T:
10
0%
HU
| M
H
50
% H
P | S
P
10
0%
HU
| M
H
9
2.1
1%
HP
| S
P
9
9 K
K | H
C
S
AS
AR
AN
T
AR
GE
T:
10
0%
HU
| M
H
7
5%
HP
| S
P
4
0 K
K | H
C
10
0%
HU
| M
H
1
00
% H
P | S
P
2
02
KK
| H
C
S
AS
AR
AN
T
AR
GE
T:
10
0%
HU
| M
H
1
00
% H
P | S
P
1
10
KK
| H
C
10
0%
HU
| M
H
97
% H
P | S
P
(3
7/3
8)1
15
4 K
K2 |
HC
96
% H
XP
| N
SP
SA
SA
RA
N
TA
RG
ET
: 1
00
% H
U | M
H
1
00%
HP
| S
P
2
00
KK
| H
C
10
0%
HX
P | N
SP
56 PROGRAM FARMASI / PHARMACY PROGRAMME
LAPORAN TAHUNANANNUAL REPORT2012
L
AM
PIR
AN
9
| L
ap
or
an
T
ah
un
an
2
01
2
B. P
ENG
UATK
UASA
AN
FA
RMA
SI |
PHA
RMA
CY
ENFO
RCEM
ENT
BIL
.
No
.
KP
I
KP
I
PE
NC
AP
AIA
N A
CH
IEV
EM
EN
TS
2
00
9
20
10
20
11
20
12
1.
P
era
tus p
en
ge
lua
ran
le
se
n/p
erm
it b
aru
ya
ng
dik
elu
ark
an
di
ba
wa
h
Akta
R
acu
n
19
52
dala
m t
em
po
h 1
0 h
ari b
eke
rja
Issu
an
ce
of
lice
nse/p
erm
it (
un
de
r P
ois
on
Act
195
2)
with
in 1
0 w
ork
ing d
ays
91
.2%
SA
SA
RA
N
TA
RG
ET
: 9
0%
97
.7%
SA
SA
RA
N
TA
RG
ET
: 90
%
99
.7%
SA
SA
RA
N
TA
RG
ET
: 1
00%
99
.1%
SA
SA
RA
N
TA
RG
ET
: 1
00
%
2.
P
era
tus
inte
llig
ence
sa
mple
ya
ng
p
ositif
me
ng
an
dun
gi
ba
ha
n
terl
ara
ng
b
erb
an
din
g
jum
lah
sa
mp
el p
rod
uk y
an
g d
iuji
Inte
llige
nce
sa
mp
les
teste
d
po
sitiv
e
for
pro
hib
ited
su
bsta
nces
56
%
S
AS
AR
AN
T
AR
GE
T:
70
%
62
.1%
SA
SA
RA
N
TA
RG
ET
: 70
%
81
.1%
SA
SA
RA
N
TA
RG
ET
: 7
0%
80
.2%
SA
SA
RA
N
TA
RG
ET
: 7
0%
3.
P
era
tus s
erb
ua
n y
an
g b
erj
aya
un
tuk d
iam
bil
tind
aka
n
un
dan
g-u
nd
an
g
darip
ad
a
jum
lah
serb
ua
n y
an
g d
ijala
nka
n
Su
cce
ssfu
l ra
ids r
esu
ltin
g in
le
ga
l a
ctio
ns
94
.4%
SA
SA
RA
N
TA
RG
ET
: 7
5%
94
.5%
SA
SA
RA
N
TA
RG
ET
: 75
%
98
.2%
SA
SA
RA
N
TA
RG
ET
: 9
5%
99
.6%
SA
SA
RA
N
TA
RG
ET
: 9
5%
57PROGRAM FARMASI / PHARMACY PROGRAMME
LAPORAN TAHUNANANNUAL REPORT 2012
L
AM
PIR
AN
1
0 | L
ap
or
an
T
ah
un
an
2
01
2
C. B
AHA
GIA
N D
ASA
R DA
N P
ENG
URUS
AN
FA
RMA
SI |
PHA
RMA
CY
POLIC
Y A
ND
MA
NA
GEM
ENT
BIL
.
No
.
KP
I
KP
I
PE
NC
AP
AIA
N A
CH
IEV
EM
EN
TS
2
00
9
2
010
2
01
1
20
12
1.
P
era
tus
Pe
ga
wa
i F
arm
asi
yan
g
me
nca
pa
i
ma
ta m
inim
um
C
PD
ya
ng
d
ite
tapka
n d
ala
m
ma
sa s
eta
hu
n:
•
Ja
nu
ari
– M
ac
: 1
0 m
ata
•
Ja
nu
ari
– J
un
: 2
0 m
ata
•
Ja
nu
ari
– S
ep
tem
be
r :
30
mata
•
Ja
nu
ari
– D
ise
mb
er
:
40 m
ata
Pe
rce
nta
ge
o
f p
harm
acis
ts
me
eting
th
e
min
imu
m C
PD
po
ints
se
t in
a y
ea
r:
•
Ja
nu
ary
– M
arc
h
:
10
po
ints
•
Ja
nu
ary
– J
un
e
: 2
0 p
oin
ts
•
Ja
nu
ary
– S
ep
tem
ber:
30
po
ints
•
Ja
nu
ary
– D
ecem
be
r : 4
0 p
oin
ts
100
%
S
AS
AR
AN
T
AR
GE
T:
10
0%
PF
di Ib
u
Pe
jab
at
BP
F d
an
B
PF
K
1
00
% p
harm
acis
ts a
t P
SD
an
d B
PF
K H
Q
97
.7%
SA
SA
RA
N
TA
RG
ET
: 1
00
% P
F d
i Ib
u
Pe
jab
at
BP
F d
an
B
PF
K
1
00
% p
harm
acis
ts
at
PS
D a
nd
BP
FK
H
Q
99
%
S
AS
AR
AN
T
AR
GE
T:
100
% P
F s
elu
ruh
ne
ga
ra
1
00
% p
ha
rma
cis
t na
tio
nw
ide
99
.7%
SA
SA
RA
N
TA
RG
ET
: 10
0%
PF
selu
ruh
n
eg
ara
10
0%
pha
rmacis
ts
na
tio
nw
ide
2.
P
era
tus
pe
rbe
lan
jaa
n
p
eru
ntu
ka
n
latih
an
d
ala
m P
erk
hid
ma
tan
P
erc
en
tag
e
of
expe
nd
iture
fo
r o
rga
niz
ing
tr
ain
ing
in t
he
co
un
try
99
.3%
SA
SA
RA
N
TA
RG
ET
:
95
%
81
.65%
SA
SA
RA
N
TA
RG
ET
:
95
%
Dig
ugu
rka
n d
an
dig
an
tika
n d
en
ga
n
ind
ika
tor
(3)
Dro
ppe
d a
nd
re
pla
ce
d w
ith in
dic
ato
r (3
)
58 PROGRAM FARMASI / PHARMACY PROGRAMME
LAPORAN TAHUNANANNUAL REPORT2012
L
AM
PIR
AN
1
1 | L
ap
or
an
T
ah
un
an
2
01
2
BIL
.
No
.
KP
I
KP
I
PE
NC
AP
AIA
N A
CH
IEV
EM
EN
TS
2
00
9
2
010
2
01
1
20
12
3.
P
era
tus
pe
rbe
lan
jaa
n
ke
se
luru
ha
n
be
lan
ja
me
ng
uru
s
(B42
) B
ah
ag
ian
P
erk
hid
ma
tan
Farm
asi (ib
u p
eja
bat)
•
Ja
nu
ari
– M
ac
: 2
0%
•
Ja
nu
ari
– J
un
:
45
%
•
Ja
nu
ari
– S
ep
tem
be
r : 7
5%
•
Ja
nu
ari
– D
ise
mb
er
: 1
00
%
Ca
tata
n:
Ind
ika
tor
ini
mula
dip
an
tau s
eb
ag
ai
KP
I pa
da
tah
un 2
01
1
Pe
rce
nta
ge
of to
tal exp
en
ditu
re P
SD
(H
Q)
•
Ja
nu
ary
– M
arc
h
: 2
0%
•
Ja
nu
ary
– J
un
e
:
45
%
•
Ja
nu
ary
– S
ep
tem
ber
: 7
5%
•
Ja
nu
ary
– D
ecem
be
r : 1
00
%
No
te:
Ind
ica
tor
ha
d b
ee
n m
on
ito
red a
s K
PI
sin
ce
201
1
Ke
selu
ruh
an
T
ota
l :
97
.87
%
D
asa
r &
P
en
gu
rusa
n
Farm
asi
P
harm
acy P
olic
y &
M
ana
ge
me
nt:
97
.44
%
A
ma
lan
&
Pe
rke
mb
an
ga
n
Farm
asi
P
harm
acy P
ractice
&
De
ve
lop
me
nt:
96
.80
%
P
en
gu
atk
uasa
an
F
arm
asi
P
ha
rma
cy
En
forc
em
en
t:
98
.79
%
S
AS
AR
AN
T
AR
GE
T:
>9
5%
Ke
se
luru
ha
n
To
tal:
9
9.1
1%
Dasa
r &
P
en
gu
rusa
n
Fa
rma
si
P
ha
rma
cy P
olic
y &
M
an
age
me
nt:
9
9.4
1%
Am
ala
n &
P
erk
em
ba
ng
an
F
arm
asi
P
ha
rma
cy P
ractice
&
Deve
lop
me
nt:
98
.61
%
P
en
gu
atk
ua
saa
n
Fa
rma
si
P
harm
acy
En
forc
em
en
t:
99
.16%
SA
SA
RA
N
TA
RG
ET
: >
95%
Ke
se
luru
ha
n
To
tal:
9
8.4
0%
Dasa
r &
P
en
gu
rusan
F
arm
asi
P
ha
rma
cy P
olic
y &
M
an
ag
em
en
t:
98
.25%
Am
ala
n &
P
erk
em
ba
ng
an
F
arm
asi
P
ha
rma
cy P
olic
y &
M
an
ag
em
en
t:
96
.72
%
P
en
gu
atk
ua
saa
n
Fa
rma
si
P
harm
acy
En
forc
em
en
t:
99
.93%
SA
SA
RA
N
TA
RG
ET
: >
95%
Ke
se
luru
ha
n
To
tal:
9
8.8
1%
Da
sa
r &
P
en
gu
rusan
F
arm
asi
P
harm
acy P
olic
y &
M
an
ag
em
en
t:
99
.0%
Am
ala
n
&P
erk
em
ba
ng
an
F
arm
asi
P
harm
acy P
ractice
&
de
ve
lop
me
nt:
99.6
4%
Pe
ng
ua
tku
asa
an
F
arm
asi
P
ha
rma
cy
En
forc
em
en
t:
99.4
6%
SA
SA
RA
N
TA
RG
ET
: >
95
%
59PROGRAM FARMASI / PHARMACY PROGRAMME
LAPORAN TAHUNANANNUAL REPORT 2012
L
AM
PIR
AN
1
2 | L
ap
or
an
T
ah
un
an
2
01
2
BIL
.
No
.
KP
I
KP
I
PE
NC
AP
AIA
N A
CH
IEV
EM
EN
TS
2
00
9
2
010
2
01
1
20
12
4.
*P
era
tus
Peg
aw
ai
Fa
rma
si
yan
g
me
nd
ap
at
Ija
za
h
Sa
rja
na
/D
okto
r F
als
afa
h
se
lep
as
me
neri
ma
C
uti
Be
laja
r B
erg
aji
Pen
uh
(de
ng
an
ata
u t
an
pa
bia
sis
wa
)
Ca
tata
n:
*Mula
i 2
011
, d
ipin
da
dari k
enyata
an a
sal:
“Bila
ngan P
egaw
ai F
arm
asi yang M
ela
nju
tkan P
eng
ajia
n
ke
Peringkat
Ijaza
h
Lan
juta
n
Sarjana
dan
Dokto
r
Fals
afa
h d
ala
m P
elb
aga
i B
idang d
an K
epakara
n”.
*Perc
en
tag
e
of
Ph
arm
acis
ts
wh
o
ea
rns
a
Ma
ste
rs/P
hD
aft
er
rece
ivin
g
full
pa
id
stu
dy
lea
ve
(w
ith
or
with
ou
t sch
ola
rsh
ip)
No
te:
*Fro
m 2
011, as a
mended fro
m o
rigin
al s
tate
ment:
“The num
ber
of
pharm
acis
ts w
ho purs
ue an M
BA
and
PhD
in
various fie
lds a
nd
expert
ise”
46
%
S
AS
AR
AN
T
AR
GE
T:
20
%
17
5
S
AS
AR
AN
T
AR
GE
T :
15
%
10
0%
SA
SA
RA
N
TA
RG
ET
:
95
%
100
%
S
AS
AR
AN
T
AR
GE
T :
9
5%
60 PROGRAM FARMASI / PHARMACY PROGRAMME
LAPORAN TAHUNANANNUAL REPORT2012
L
AM
PIR
AN
1
3 | L
ap
or
an
T
ah
un
an
2
01
2
D. B
IRO
PEN
GA
WA
LAN
FA
RMA
SEUT
IKA
L KE
BAN
GSA
AN
| N
ATIO
NA
L PH
ARM
AC
EUTIC
AL
CO
NTR
OL
BURE
AU
BIL.
N
o.
KPI
KPI
PEN
CAPA
IAN
ACH
IEVE
MEN
TS
2009
20
10
2011
2012
1.
*Pe
ratu
s
pe
nin
gkata
n
pe
mb
eri
an
Lese
n/K
eb
en
ara
n
me
ng
ilan
g
bag
i p
rod
uk
farm
ase
utika
l, t
radis
ion
al da
n k
osm
etik
(p
en
ing
kata
n a
da
lah
be
rda
sark
an
pu
rata
3
tah
un
se
be
lum
nya
) C
ata
tan
*M
ula
i 2010
dip
inda d
ari
ind
ikato
r asal:
“Bila
ngan
Lesen/
Kebenara
n
Mengila
ng
Bag
i P
roduk
Farm
aseutik
al, T
radis
iona
l D
an K
osm
etik
”.
*Issu
ance
of
lice
nce/p
erm
it f
or
pro
du
ctio
n o
f p
ha
rma
ce
utica
ls,
trad
itio
na
l a
nd
co
sm
etic
pro
du
cts
(in
cre
ase is b
ase
d o
n t
he
pre
vio
us 3
ye
ar
ave
rag
e)
No
te
*Sin
ce 2
01
0, as a
mended fro
m o
rigin
al s
tate
ment:
“Num
ber
of
pro
ductio
n lic
ense/p
erm
it fo
r pharm
aceutic
al,
traditio
na
l and c
osm
etic
pro
ducts
”.
487
SA
SA
RA
N
TA
RG
ET
:
380
51
9
(25
.4%
pe
nin
gka
tan
)
(25
.4%
incre
ase
)
SA
SA
RA
N
TA
RG
ET
:
11
%
pe
nin
gkata
n
(1
1%
in
cre
ase
)
(~4
60
lese
n/
ke
be
nara
n
me
ng
ilan
g )
(~46
0 p
rod
uctio
n
lice
nse
/pe
rmit)
55
5
(19
.9%
pe
nin
gka
tan
)
(19.9
% in
cre
ase
)
SA
SA
RA
N
TA
RG
ET
:
14
%
pe
nin
gkata
n
(1
4%
in
cre
ase
)
(~5
30
lese
n/
ke
be
na
ran
m
eng
ilan
g)
(~
53
0 p
rod
uctio
n
lice
nse
/perm
it)
575
(1
0.6
%
pe
nin
gkata
n)
(1
0.6
% in
cre
ase)
S
AS
AR
AN
T
AR
GE
T:
7.5
%
pe
nin
gka
tan
(7.5
% in
cre
ase
)
(~5
60
le
se
n/
ke
ben
ara
n
men
gila
ng)
(~
56
0 p
rod
uctio
n
lice
nse/p
erm
it)
2.
Bila
ng
an
p
rod
uk
be
rda
fta
r d
an
ko
sm
etik
bern
otifika
si
da
lam
p
asa
ran
ya
ng
d
ipa
nta
u
bag
i tu
jua
n
kese
lam
ata
n d
an
ku
alit
i N
um
be
r of
no
tifie
d re
gis
tere
d a
nd
co
sm
etic
pro
du
cts
in
th
e m
ark
et
wh
ich
is m
on
ito
red
for
safe
ty a
nd
qua
lity
2,9
31
pro
du
k
2,9
31
pro
ducts
SA
SA
RA
N
TA
RG
ET
: 2,5
00
3,0
13
pro
du
k
3,0
13
pro
du
cts
SA
SA
RA
N
TA
RG
ET
: 2
,50
0
3,2
84
pro
du
k
3,2
84
pro
du
cts
SA
SA
RA
N
TA
RG
ET
: 3
,00
0
3,3
05
pro
du
k
3,3
05
pro
du
cts
SA
SA
RA
N
TA
RG
ET
: 3
,30
0
L
AM
PIR
AN
1
4 | L
ap
or
an
T
ah
un
an
2
01
2
BIL.
N
o.
KPI
KPI
PEN
CAPA
IAN
ACH
IEVE
MEN
TS
2009
20
10
2011
2012
3.
Pe
ng
ga
lakka
n
pe
lap
ora
n
Ad
vers
e
Dru
g
Re
actio
n (
AD
R).
P
rom
otin
g
rep
ort
ing
o
f A
dvers
e
Dru
g
Re
actio
n (
AD
R).
5,8
50
SA
SA
RA
N
TA
RG
ET
: 5,0
00
7,0
79
SA
SA
RA
N
TA
RG
ET
: 7
,20
0
(~ 2
00
AD
R p
er
juta
po
pu
lasi)
(~2
00
AD
Rs p
er
mill
ion
po
pula
tion
)
9,3
85
SA
SA
RA
N
TA
RG
ET
: 9
,50
0
(~ 2
00
AD
R p
er
juta
po
pu
lasi)
(~2
00
AD
Rs p
er
mill
ion
po
pula
tion
)
10
,10
2
S
AS
AR
AN
T
AR
GE
T:
9,5
00
(
~ 2
00
AD
R p
er
juta
po
pula
si)
(~
20
0 A
DR
s p
er
mill
ion
po
pu
latio
n)
61PROGRAM FARMASI / PHARMACY PROGRAMME
LAPORAN TAHUNANANNUAL REPORT 2012
L
AM
PIR
AN
1
5 | L
ap
or
an
T
ah
un
an
2
01
2
Jad
ual
3:
Bilan
gan
Klin
ik K
esih
ata
n Y
an
g M
en
aw
ark
an
Sis
tem
Te
mu
jan
ji M
en
ga
mb
il U
bat
di
Fa
rmas
i k
ep
ad
a p
esak
it y
an
g
men
eri
ma r
aw
ata
n jan
gk
a p
an
jan
g b
ag
i ta
hu
n 2
010
-2012
Tab
le 3
: N
um
ber
of
He
alt
h C
lin
ic P
harm
acie
s O
fferi
ng
Ph
arm
ac
y A
pp
oin
tmen
ts S
yste
m f
or
pati
en
ts r
ece
ivin
g l
on
g-t
erm
tre
atm
en
t fo
r 2
010-2
012
Tah
un
| Y
ear
20
10
20
11
201
2
Bil.
Klin
ik K
esih
ata
n y
an
g m
en
aw
ark
an S
iste
m T
em
uja
nji
Men
ga
mb
il U
bat
di
Farm
asi
kep
ad
a
pe
sa
kit
ya
ng
men
eri
ma
ra
wa
tan
ja
ng
ka
pa
nja
ng.
Nu
mb
er
of
He
alth
Clin
ic O
ffe
rin
g P
ha
rma
cy A
pp
oin
tmen
ts
Syste
m f
or
Pa
tie
nts
Re
ceiv
ing
Lo
ng-T
erm
Tre
atm
en
t
20
1
386
4
65
Jad
ual
4:
Pe
ratu
s p
resk
rip
si
ya
ng
Berj
aya
did
isp
en
dala
m m
asa 3
0 m
init
(20
10-2
012
)
Tab
le 4
: P
erc
en
tag
e o
f P
res
cri
pti
on
s d
isp
en
sed
wit
hin
30 m
inu
tes (
201
0-2
01
2)
Tah
un
| Y
ear
20
10
201
1
201
2
Pe
ratu
s P
reksrip
si
ya
nd
did
isp
ens
Perc
enta
ge o
f
Pre
scri
ption
s
dis
pen
sed
96
.6%
96
.3%
95
.29
%
62 PROGRAM FARMASI / PHARMACY PROGRAMME
LAPORAN TAHUNANANNUAL REPORT2012
L
AM
PIR
AN
1
6 | L
ap
or
an
T
ah
un
an
2
01
2
Ra
jah
2 :
Ak
tivit
i P
en
ilaia
n F
arm
ako
eko
no
mik
Fig
ure
2:
Ph
arm
aco
eco
no
mic
s E
valu
ati
on
Acti
vit
ies
* P
erb
andin
gan u
ba
t :
Bila
ngan u
bat
(Pro
form
a B
dan P
rofo
rma D
) ya
ng d
ibua
t perb
andin
gan d
enga
n a
ltern
ative s
edia
ada d
ala
m F
orm
ula
ri U
bat
Kem
ente
rian K
esih
ata
n M
ala
ysia
(FU
KK
M)
*Dru
g C
om
parison: N
o. of dru
gs (
Pro
form
a B
and P
rofo
rma D
) com
pare
d w
ith a
ltern
ativ
es r
eadily
availa
ble
in
the
Min
istr
y o
f H
ealth
Dru
g F
orm
ula
ry
* D
rug R
evie
w: B
ilang
an u
ba
t ya
ng
dib
uat pen
ilaia
n lengkap d
ari
segi k
esela
mata
n, efikasi dan
cost-
effectiv
eness b
agi ubat baru
(P
rofo
rma D
)
* D
rug R
evie
w: N
o. of new
dru
gs m
ade a
com
ple
te e
valu
ation o
f safe
ty, e
ffic
acy a
nd c
ost-
effectiv
eness (
Pro
form
a D
)
2008
2009
2010
2011
2012
Perb
andi
ngan
uba
t 27
132
722
227
122
1
Drug
revi
ew31
3930
4138
051015202530354045
050100
150
200
250
300
350
Bilangan drug review
Bilanagan perbandingan ubat
63PROGRAM FARMASI / PHARMACY PROGRAMME
LAPORAN TAHUNANANNUAL REPORT 2012
L
AM
PIR
AN
1
7 | L
ap
or
an
T
ah
un
an
2
01
2
AKT
IVITI
PEN
GUA
TKUA
SAA
N F
ARM
ASI
ENFO
RCEM
ENT P
HARM
AC
Y A
CTIV
ITIES
JU
ML
AH
NIL
AI
RA
MP
AS
AN
PE
NG
UA
TK
UA
SA
AN
FA
RM
AS
I 2
01
0-2
012
V
AL
UE
OF
IT
EM
S S
EIZ
ED
BY
PH
AR
MA
CY
EN
FO
RC
EM
EN
T 2
010
-2012
Ram
pasa
n (
RM
) M
en
gik
ut S
erb
uan,
Pem
eri
ksaan d
an
Pin
tu M
asuk T
ah
un
20
10
-201
2
Valu
e S
eiz
ed
(R
M)
acco
rdin
g to
Raid
ing,
Insp
ectio
n a
nd
Entr
y P
oin
t fo
r yea
r 2
010-2
01
2
Tah
un
Y
ear
Se
rbu
an
R
aid
P
em
eri
ks
aan
In
sp
ec
tio
n
Pin
tu M
asu
k
En
try
Po
int
Ju
mla
h
To
tal
Bil
. N
o. o
f It
em
s
Nila
i (R
M)
Va
lue (
RM
) B
il.
No
. o
f It
em
s
Nil
ai
(RM
) V
alu
e (
RM
) B
il.
No
. o
f It
em
s
Nil
ai (R
M)
Va
lue (
RM
) B
il.
No
. o
f It
em
s
Nila
i (R
M)
Va
lue (
RM
)
201
0
16,8
62
22
,00
0,0
47
6,0
39
37
1,7
35
6,8
69
1,7
56
,563
29
,770
24,1
28,3
45
201
1
22,9
70
27
,46
1,9
97
7,8
97
70
8,1
52
7,4
50
2,4
36
,019
38
,317
30,6
06,1
68
201
2
25,2
79
23
,36
1,0
91
4,5
67
35
5,6
50
14,8
11
2,6
19
,048
44
,657
26,3
35,7
89
L
AM
PIR
AN
1
8 |
La
po
ra
n
Ta
hu
na
n
20
12
Ram
pasa
n M
en
gik
ut K
ate
go
ri P
roduk T
ah
un
20
10
-201
2
Valu
e S
eiz
ed
(R
M)
acco
rdin
g to
Pro
du
k C
ate
go
ry f
or
ye
ar
20
10
-201
2
Ta
hu
n
Ye
ar
Kelu
ara
n B
erd
aft
ar
Reg
iste
red
Pro
du
cts
(A
, X
, T
, K
)
Kelu
ara
n T
idak
Be
rdaft
ar
Un
reg
iste
red
Pro
du
cts
(A
, X
, T
, K
, la
in-l
ain
/ o
thers
)
Lain
-Lain
* O
thers
* J
um
lah
T
ota
l
Bil
. N
o. o
f It
em
s
Nila
i (R
M)
Valu
e (
RM
) B
il.
No
. o
f It
em
s
Nil
ai (R
M)
Va
lue (
RM
) B
il.
No
. o
f It
em
s
Nila
i (R
M)
Valu
e (
RM
) B
il.
No
. o
f It
em
s
Nil
ai (R
M)
Va
lue (
RM
)
20
10
4,8
72
2,3
86,1
19
24,8
52
21
,569
,31
0
46
17
2,9
16
29,7
70
24
,128
,34
5
20
11
3,9
80
6,9
74,3
60
33,2
94
22
,534
,94
3
1,0
43
1,0
96,8
65
38,3
17
30
,606
,16
8
20
12
4,5
01
2,5
71,0
28
40,0
06
23
,72
7,5
75
15
0
37
,18
6
44,6
57
26
,335
,78
9
A =
Racu
n, X
= O
TC
, T
= T
radis
ion
al, K
= K
osm
etik;
Lain
-lain
: V
ete
rinar,
Pre
ku
rsor,
Ba
han
Kim
ia, B
aha
n M
enta
h,
lain
-lain
A
= P
ois
on,
X =
OT
C,
T =
Tra
ditio
nal, K
= C
osm
etic;
Oth
ers
: V
ete
rina
ry,
Pre
curs
or,
Ch
em
ical, P
ha
rma
ce
utical R
aw
Mate
ria
l, e
tc.
64 PROGRAM FARMASI / PHARMACY PROGRAMME
LAPORAN TAHUNANANNUAL REPORT2012
L
AM
PIR
AN
1
9 | L
ap
or
an
T
ah
un
an
2
01
2
PRO
SEC
UTIO
N |
PEN
DAKW
AA
N
Pen
da
kw
aan
ad
ala
h b
erd
asa
rka
n e
mp
at
akta
ya
ng
uta
ma
sep
ert
i d
i b
aw
ah
. S
ep
an
jan
g t
ah
un 2
01
2,
se
jum
lah 1
,05
7 k
es t
ela
h s
ele
sa
i d
ida
kw
a
de
ng
an
ju
mla
h k
utip
an
de
nd
a s
eb
an
ya
k R
M3,3
83
,20
0.0
0.
Ca
se
s w
ere
pro
secu
ted
ba
se
d o
n f
ou
r m
ain
acts
. A
to
tal
of
1,0
57 c
ase
s w
ere
co
mp
lete
ly p
rose
cute
d i
n 2
01
2 w
ith
th
e t
ota
l co
llectio
n o
f R
M
3,3
83,2
00
.00
of
fin
es c
olle
cte
d.
PE
ND
AK
WA
AN
(S
EL
ES
AI)
BE
RD
AS
AR
KA
N A
KT
A D
AN
NE
GE
RI
(20
12
)
PR
OS
EC
UT
ION
(C
OM
PL
ET
ED
) B
Y A
CT
S A
ND
ST
AT
ES
(2
01
2)
AK
TA
A
CT
Ak
ta
Ra
cu
n
195
2
Po
iso
n
Act
19
52
Ak
ta R
acu
n
19
52
(B
ah
an
P
sik
otr
op
ik)
Po
iso
n A
ct
195
2
(Ps
ych
otr
op
ic
Su
bs
tan
ces)
Ak
ta
Ju
ala
n
Dad
ah
1
95
2
Sa
les o
f D
rug
A
cts
1
95
2
Ak
ta U
bat
(Ikla
n &
Ju
ala
n)
195
6
Me
dic
ine A
ct
(Sale
s a
nd
A
dv
ert
isem
en
t)
195
6
Akta
P
en
daft
ara
n
Ah
li
Fa
rma
si
19
51
R
eg
istr
ati
on
o
f P
ha
rmac
ist
Ac
t 1
95
1
JU
ML
AH
T
OT
AL
Bil
. K
es
No
. o
f c
as
e
40
4
46
5
53
54
0
1,0
57
K
uti
pan
D
en
da
Fin
e
Co
lle
cti
on
67
0,4
00
17
1,8
00
2,3
60
,050
18
0,9
50
0
3,3
83
,200
65PROGRAM FARMASI / PHARMACY PROGRAMME
LAPORAN TAHUNANANNUAL REPORT 2012
L
AM
PIR
AN
2
0 | L
ap
or
an
T
ah
un
an
2
01
2
PELE
SEN
AN
DA
N K
AW
ALA
N B
AHA
N |
LIC
ENSI
NG
& S
UBST
AN
CES
CO
NTR
OL
Je
nis
da
n b
ila
ng
an
le
se
n/p
erm
it y
an
g d
ike
lua
rka
n o
leh
Ca
wa
ng
an
Pe
ng
ua
tku
asa
an
Ne
ge
ri d
i se
pa
nja
ng
ta
hu
n 2
01
2 b
erb
an
din
g d
en
ga
n
tah
un
20
10
da
n 2
01
1.
Th
e t
yp
es a
nd
nu
mb
er
of
licen
ce
s issu
ed
by S
tate
PE
Bs in 2
01
2 a
s c
om
pa
red t
o 2
01
0 a
nd
20
11.
Jen
is L
es
en
/ P
erm
it
Typ
e o
f L
icen
ce/ P
erm
it
Bil
Le
sen
/ P
erm
it
N
um
ber
of
Lic
en
ce
/Perm
it
20
10
2
01
1
20
12
Le
se
n R
acu
n J
en
is A
/P
ois
on
Lic
en
ce
Typ
e A
3,1
87
3
,31
4
3,8
19
Le
se
n R
acu
n J
en
is B
/ P
ois
on
Lic
en
ce
Typ
e B
1,6
68
1
70
8
1,8
11
Le
se
n R
acu
n J
en
is D
/ P
ois
on
Lic
en
ce
Typ
e D
9
-
-
Le
se
n R
acu
n J
en
is E
/ P
ois
on
Lic
en
ce
Typ
e E
3
0
28
3
5
Perm
it N
aO
H/
Na
OH
Pe
rmit
1,9
87
2
,11
6
2,2
56
Perm
it P
sik
otr
op
ik /
Psych
otr
op
ic P
erm
it
- 3
53
3
95
Keb
en
ara
n im
po
rt d
ad
ah
berb
ah
aya/
Impo
rt
Auth
ori
sa
tion
Fo
r D
ang
ero
us D
rug
16
5
20
4
18
4
Keb
en
ara
n e
ksp
ort
da
da
h b
erb
ah
aya/
Exp
ort
A
uth
ori
sa
tion
Fo
r D
ang
ero
us D
rug
2
5
22
1
6
Keb
en
ara
n im
po
rt b
ah
an
psik
otr
op
ik/ Im
po
rt
Auth
ori
sa
tion
Fo
r P
sycho
tro
pic
Sub
sta
nce
s
24
6
26
6
20
6
Keb
en
ara
n e
ksp
ort
ba
ha
n p
sik
otr
op
ik/
Exp
ort
A
uth
ori
sa
tion
Fo
r P
sycho
tro
pic
Sub
sta
nce
s
64
41
3
0
Jum
lah
& F
ee D
ikut
ip (R
M)/
Tot
al &
Fee
Co
llect
ed
7,38
1 8,
052
8,75
2
L
AM
PIR
AN
2
1 | L
ap
or
an
T
ah
un
an
2
01
2
Jen
is k
elu
lus
an
/ T
yp
e o
f A
pp
roval
20
10
201
1
20
12
Perm
it d
i ba
wa
h P
eri
nta
h K
asta
m / P
erm
it
Un
de
r C
usto
ms O
rde
r
Lara
ng
an I
mp
ort
/ Im
po
rt P
roh
ibitio
n
24
4
43
2
384
Lara
ng
an E
ksp
ort
/ E
xp
ort
Pro
hib
itio
n
64
4
68
6
775
Ob
liga
si d
i b
aw
ah
Art
icle
12
, 1
98
8
Co
nve
ntio
n/
Ob
liga
tio
n U
nd
er
Art
icle
12
, 19
88
C
on
ve
ntio
n
Ma
klu
mb
ala
s P
EN
/ P
EN
Fe
ed
ba
ck
1,8
47
1,9
09
2,2
27
PE
N d
ike
lua
rkan
/ P
EN
Issu
ed
7
02
71
7
761
Sura
t ke
ben
ara
n E
ksp
ort
Pe
rse
dia
an
Me
nga
nd
un
gi P
reku
rso
r/ L
ette
r o
f A
uth
ori
sa
tio
n fo
r P
rep
ara
tio
n C
on
tain
ing
Pre
cu
rsor
93
* M
ula
i 1 J
anuari 2
011
pers
edia
an in
i d
imasukkan
ke d
ala
m L
ara
ngan E
ksport
/ S
tart
ing 1
January
2011, th
e
pre
para
tion h
as b
een
in
clu
ded
under
Export
P
rohib
itio
n
Sura
t ke
ben
ara
n E
ksp
ort
Pe
rse
dia
an
Me
nga
nd
un
gi D
extr
om
eth
op
han
/ L
ett
er
of
Au
thorisa
tion
fo
r P
rep
ara
tio
n C
on
tain
ing
De
xtr
om
eth
op
ha
n
21
4
0
18
66 PROGRAM FARMASI / PHARMACY PROGRAMME
LAPORAN TAHUNANANNUAL REPORT2012
L
AM
PIR
AN
2
1 | L
ap
or
an
T
ah
un
an
2
01
2
Jen
is k
elu
lus
an
/ T
yp
e o
f A
pp
roval
20
10
201
1
20
12
Perm
it d
i ba
wa
h P
eri
nta
h K
asta
m / P
erm
it
Un
de
r C
usto
ms O
rde
r
Lara
ng
an I
mp
ort
/ Im
po
rt P
roh
ibitio
n
24
4
43
2
384
Lara
ng
an E
ksp
ort
/ E
xp
ort
Pro
hib
itio
n
64
4
68
6
775
Ob
liga
si d
i b
aw
ah
Art
icle
12
, 1
98
8
Co
nve
ntio
n/
Ob
liga
tio
n U
nd
er
Art
icle
12
, 19
88
C
on
ve
ntio
n
Ma
klu
mb
ala
s P
EN
/ P
EN
Fe
ed
ba
ck
1,8
47
1,9
09
2,2
27
PE
N d
ike
lua
rkan
/ P
EN
Issu
ed
7
02
71
7
761
Sura
t ke
ben
ara
n E
ksp
ort
Pe
rse
dia
an
Me
nga
nd
un
gi P
reku
rso
r/ L
ette
r o
f A
uth
ori
sa
tio
n fo
r P
rep
ara
tio
n C
on
tain
ing
Pre
cu
rsor
93
* M
ula
i 1 J
anuari 2
011
pers
edia
an in
i d
imasukkan
ke d
ala
m L
ara
ngan E
ksport
/ S
tart
ing 1
January
2011, th
e
pre
para
tion h
as b
een
in
clu
ded
under
Export
P
rohib
itio
n
Sura
t ke
ben
ara
n E
ksp
ort
Pe
rse
dia
an
Me
nga
nd
un
gi D
extr
om
eth
op
han
/ L
ett
er
of
Au
thorisa
tion
fo
r P
rep
ara
tio
n C
on
tain
ing
De
xtr
om
eth
op
ha
n
21
40
18
67PROGRAM FARMASI / PHARMACY PROGRAMME
LAPORAN TAHUNANANNUAL REPORT 2012
L
AM
PIR
AN
2
2 | L
ap
or
an
T
ah
un
an
2
01
2
PEM
AN
TAUA
N IK
LAN
| A
DVER
TISE
MEN
TS M
ON
ITO
RIN
G
JA
DU
AL
5:
KE
LU
LU
SA
N P
ER
MO
HO
NA
N IK
LA
N (
201
0-2
01
2)
TA
BL
E 5
: A
DV
ER
TIS
EM
EN
T A
PP
RO
VA
LS
(2
010
-201
2)
Tah
un
| Y
ear
20
10
20
11
2
012
Bil
an
ga
n P
erm
oh
on
an
Ya
ng
Dit
eri
ma
To
tal
Nu
mb
er
of
Ap
pli
cati
on
s
1, 6
02
1,6
34
2
,13
3
Ju
mla
h B
ila
ng
an
Ke
lulu
san
To
tal
Nu
mb
er
of
Ap
pro
vals
1,4
18
1,5
14
1
,67
6
Ju
mla
h B
ila
ng
an
Tid
ak
Lu
lus
To
tal
Nu
mb
er
of
No
t A
pp
rov
ed
43
2
5
17
Ju
mla
h B
ila
ng
an
Tid
ak
Pe
rlu
Ke
lulu
sa
n
To
tal
Nu
mb
er
of
No
t R
eq
uir
ed
Ap
pro
va
ls
57
2
2
18
Yu
ran
Dik
uti
p (
RM
)
Fe
es
Co
lle
cte
d (
RM
)
160
,20
0
163
,40
0
21
3,3
00
Nota
: Ju
mla
h p
erm
oho
na
n y
an
g d
ipro
se
s t
idak s
am
a d
enga
n j
um
lah
pe
rmoh
on
an
ya
ng
dite
rim
a k
era
na
terd
apa
t p
erm
oh
on
an
-pe
rmoh
on
an
ya
ng
dita
ng
gu
hka
n
da
n t
ert
utu
p s
eca
ra a
uto
ma
tik ji
ka
ma
klu
mb
ala
s d
ari p
em
oh
on
tid
ak d
ite
rim
a s
ele
pa
s te
mp
oh
pe
na
ng
gu
han
ya
ng
dib
erikan (
1 b
ula
n d
ari t
arikh
su
rat
dik
elu
ark
an).
N
ote
s:
To
tal n
o.
of
app
lica
tio
n p
rocesse
d is n
ot
the
sam
e a
s t
ota
l n
o.
of
ap
plic
atio
n r
ece
ive
d a
s t
he
re a
re f
ew
ap
plic
atio
ns w
ithh
old
or
clo
se
d a
uto
matic
ally
sin
ce
the
re is n
o r
esp
on
se f
rom
th
e a
pp
lica
nt
afte
r th
e d
ate
line
giv
en
(1
mo
nth
fro
m t
he
da
te o
f le
tte
r is
su
ed
)
68 PROGRAM FARMASI / PHARMACY PROGRAMME
LAPORAN TAHUNANANNUAL REPORT2012
L
AM
PIR
AN
2
3 | L
ap
or
an
T
ah
un
an
2
01
2
PEN
CEG
AHA
N D
AN
KES
EDA
RAN
PEN
GG
UNA
| P
REVE
NTI
ON
AN
D C
ON
SUM
ER A
WA
REN
ESS
Ja
du
al
6:
Bil
an
ga
n C
era
ma
h,
Pam
era
n P
en
did
ika
n d
an
Dia
log
(2
01
0-2
01
2)
Ta
ble
6:
Nu
mb
er
of
Ta
lks
, E
xh
ibit
ion
s a
nd
Dia
log
ue
s (
20
10-2
01
2)
Akti
vit
i/ A
cti
vit
y
20
10
2
011
2
01
2
Ce
ram
ah
/ T
alk
38
1
38
6
482
Pa
mera
n/ E
xh
ibit
ion
51
2
60
9
637
Dia
log
/ D
ialo
gu
e
42
72
90
69PROGRAM FARMASI / PHARMACY PROGRAMME
LAPORAN TAHUNANANNUAL REPORT 2012
LAMPIRAN
24 | L a p o r a n T a h u n a n 2 0 1 2
NPCB ‘s Key Statistics for 2012 / Statistik Utama BPFK bagi tahun 2012
Bilangan produk yang dinilai oleh PBKD Number of products reviewed by DCA
1211 produk/ products
• Produk semulajadi / Natural products = 565
• Produk Preskripsi / Prescription products = 357
• Supplemen kesihatan / Health Supplement = 161
• Produk bukan preskripsi / Non-prescription products = 83
• Veterinar / Veterinary = 45
Bilangan produk yang diluluskan untuk pendaftaran oleh PBKD Number of products approved by DCA from registration
633
Bilangan produk Ubat Baru yang didaftarakan Number of New Chemical Entity (NCE) products registered
50
Bilangan produk Bioteknologi yang didaftarkan Number of Biotechnology products registered
24
Bilangan produk yang dibatalkan Number of products cancelled
66 produk (kesemuanya adalah produk semulajadi) 66 products (all natural products)
Bilangan produk yang digantung Number of products suspended
25
• Produk Preskripsi / Prescription products = 12
• Produk semulajadi / Natural products = 13
LAMPIRAN
25 | L a p o r a n T a h u n a n 2 0 1 2
Bilangan Sijil Produk Pharmaceutical yang dikeluarkan Number of Certificate of Pharmaceutical Products (CPP) Issued
2247
Bilangan laporan kesan advers ubat yang diterima Number of Adverse Drug Reaction (ADR) reports received
10102
• 1903 (Adverse Event Following Immunisation-AEFI)
• 8199 (ADR excluding AEFI)
Bilangan sampel pengawasan yang diuji oleh makmal BPFK Number of Post Market Surveillance Sample tested by NPCB laboratory
1604
• Lulus ujian / Pass testing = 1476
• Gagal ujian / Fail testing = 128
Bilangan produk kosmetik yang dinotifikasi Number of cosmetic products notified
66913
Bilangan pembatalan notifikasi Number of notification cancellation
399
• Isu formulasi / Formulation issues = 261
• Sampel pengawasan / Surveillance sample = 74
• Isu Amalan Pengilangan Baik / Good Manufacturing Practice (GMP) Issues = 57
• Lain-lain / Others = 7
Bilangan Sijil Penjualan Bebas yang dikeluarkan Number of Certificate of Free Sale (CFS) Issued
2789
Bilangan Audit Fail Maklumat Produk Number of Product Information File (PIF) Audit
335
LAMPIRAN
26 | L a p o r a n T a h u n a n 2 0 1 2
Bilangan sampel yang diuji Number of samples tested
2769 • Lulus ujian / Pass testing = 2390 • Gagal ujian / Fail testing = 379
Bilangan sampel yang didapati mengandungi bahan campurpalsu Number of samples tested positive for adulteration
130
Bilangan penilaian protocol dan data validasi Number of Evaluations of Protocol Analysis and Analytical Validation Data
1250
Bilangan pemeriksaan Amalan Pengilangan Baik Number of Good Manufacturing Practice (GMP) inspections
299
Bilangan lessen yang dikeluarkan Number of license issued
1832 • Lesen Pemborong / Wholesaler license =
1144 • Lesen Pengimport / Import license = 410 • Lesen Pengilang / Manufacturer license =
278 Bilangan pemeriksaan Amalan Klinikal Baik & Amalan Makmal Baik Number of Good Clinical Practice & Good Laboratory Practice inspections
21
Bilangan permohonan Lesen Import Percubaan Klinikal Number of application for Clinical Trial Import License (CTIL)
282
70 PROGRAM FARMASI / PHARMACY PROGRAMME
LAPORAN TAHUNANANNUAL REPORT2012
LAMPIRAN
26 | L a p o r a n T a h u n a n 2 0 1 2
Bilangan sampel yang diuji Number of samples tested
2769 • Lulus ujian / Pass testing = 2390 • Gagal ujian / Fail testing = 379
Bilangan sampel yang didapati mengandungi bahan campurpalsu Number of samples tested positive for adulteration
130
Bilangan penilaian protokol dan data validasi Number of Evaluations of Protocol Analysis and Analytical Validation Data
1250
Bilangan pemeriksaan Amalan Pengilangan Baik Number of Good Manufacturing Practice (GMP) inspections
299
Bilangan lesen yang dikeluarkan Number of license issued
1832 • Lesen Pemborong / Wholesaler license =
1144 • Lesen Pengimport / Import license = 410 • Lesen Pengilang / Manufacturer license =
278 Bilangan pemeriksaan Amalan Klinikal Baik & Amalan Makmal Baik Number of Good Clinical Practice & Good Laboratory Practice inspections
21
Bilangan permohonan Lesen Import Percubaan Klinikal Number of application for Clinical Trial Import License (CTIL)
282
LAMPIRAN
27 | L a p o r a n T a h u n a n 2 0 1 2
Bilangan pertanyaan yang diterima oleh Helpdesk BPFK Number of enquiry received by NPCB’s Helpdesk
5971
• Telefon / Telephone = 4189
• E-mail & Modul Pertanyaan / E-mail & Enquiry module = 832
• Pertanyaan di kaunter / Walk-in = 950